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vi
Tumor cells are seen to modulate the phenotype of all major immune cells to 
express tumor favouring phenotypes. Inflammation associated with tumors, a result of 
such interaction, is increasingly being believed to play a major role in tumor initiation, 
progression and even metastasis. This modulation is achieved very early when 
Monocytes, precursors of Macrophages and DCs, from the circulating pool are recruited 
towards tumors and selectively differentiated. Monocytes, in particular, are thought to 
generate a cytokine milieu in the microenvironment favourable to tumor.  Such a 
crosstalk and the pathways involved therein are not well established, especially in human 
models. Using representative human carcinoma cells of different origin including Lung, 
Colon and Cervix, we show that factor(s) associated with these cells can activate 
secretion of tumor-associated cytokines, TNF-α, IL-6, IL-10, IL-12p40 but not IL-12p70 
or IL-1β from human monocytes. Comparative murine co-cultures are also able to induce 
similar responses. Treatment of monocytes with TLR-2 blocking antibody inhibits these 
inflammatory responses upon encountering cell-associated as well as secretory ligand(s) 
from tumor cells. Pharmacological inhibition of intracellular MAP kinase pathway in 
carcinoma cells ablates the TLR-2 agonistic activity of carcinoma cells. However, 
inhibition of EGFR and Ras, two major oncogenic players, had no such effect. Early 
inflammatory response tends to enhance the proliferation and invasiveness of tumor cells 
and concurrently, increase the viability of monocytes. These tumor associated 
inflammatory responses may well be one of the mechanisms to manipulate effector T-cell 
response against tumors. These results suggest a previously unrecognized pathway that 
may regulate inflammatory responses triggered by cancer cells from monocytes. Our 
findings have important implications for understanding Cancer related Inflammation. 
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Carcinoma
Carcinoma is the medical term for the most common type of cancer occurring in 
humans. It is defined as a cancer that begins in a tissue that lines the inner or outer 
surfaces of the body, and that generally arises from cells originating in the endodermal or 
ectodermal germ layer during embryogenesis (Berman, 2004a). More specifically, a 
carcinoma is tumor tissue derived from putative epithelial cells, having the cytological 
appearance, histological architecture, or molecular characteristics of epithelial cells
(Berman, 2004b) whose genome has become altered or damaged to such an extent that 
the cells become transformed, and begin to exhibit abnormal malignant properties.
Pathogenesis and Hallmarks of cancer
Cancer occurs when a single progenitor cell accumulates mutations and other 
changes in the DNA, histones, and other biochemical compounds that make up the cell's 
genome (Hanahan and Weinberg, 2001). Certain combinations of mutations in the given 
progenitor cell ultimately result in that cell (also called a cancer stem cell) displaying a 
number of abnormal, malignant cellular properties that, when taken together, are 
considered characteristic or hallmarks of cancer (Hanahan and Weinberg, 2001), 
including:
 the ability to continue to divide perpetually, producing an exponentially (or near-
exponentially) increasing number of new malignant cancerous "daughter cells" 
(uncontrolled mitosis);
 the ability to penetrate normal body surfaces and barriers, and to bore into or 
through nearby body structures and tissues (local invasiveness);
 the ability to spread to other sites within the body (metastasize) by penetrating or 
entering into the lymphatic vessels (regional metastasis) and/or the blood vessels
(distant metastasis) (Figure A).
If this process of continuous growth, local invasion, and regional and distant metastasis is 
not halted via a combination of stimulation of immunological defenses and medical 
treatment interventions, the end result is that the host suffers a continuously increasing 
burden of tumor cells throughout the body. Eventually, the tumor burden increasingly 
interferes with normal biochemical functions carried out by the host's organs, and death
ultimately ensues. A progenitor carcinoma stem cell can be formed from any of a number 
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of oncogenic combinations of mutations in a totipotent cell, a multipotent cell,or a mature 
differentiated cell (Figure A).
Figure A: Hallmarks of Cancer (developing cancer is centrally denoted).
Classification and types of carcinomas
Malignant neoplasms are exceptionally heterogeneous entities, reflecting the wide 
variety, intensity, and potency of various carcinogenic promoters. One commonly used 
classification scheme classifies these major cancer types on the basis of cell genesis, 
specifically, their (putative) cell (or cells) of origin (Travis et al., 2004)
1. Epithelial cells > carcinoma
2. Non-hematopoietic mesenchymal cells > sarcoma
3. Hematopoietic cells
a) bone marrow-derived cells that normally mature in the bloodstream > 
Leukemia
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b) bone marrow-derived cells that normally mature in the lymphatics > 
Lymphoma
4. Germ cells > Germinoma
Other criteria that play a role in a cancer classification, staging and diagnosis include the 
degree to which the malignant cells resemble their normal, untransformed counterparts, 
the appearance of the local tissue and stromal architecture., the anatomical location from 
which tumors arise and genetic, epigenetic, and molecular features.
Various histological types and variants of carcinoma are:
Adenocarcinoma: (adeno = gland) Refers to a carcinoma featuring microscopic 
glandular-related tissue cytology, tissue architecture, and/or gland-related molecular 
products, e.g., mucin.
Squamous cell carcinoma: Refers to a carcinoma with observable features and 
characteristics indicative of squamous differentiation (intercellular bridges, keratinization, 
squamous pearls).
Adenosquamous carcinoma: Refers to a mixed tumor containing both 
adenocarcinoma and squamous cell carcinoma, wherein each of these cell types comprise 
at least 10% of the tumor volume.
Anaplastic or Undifferentiated carcinoma: Refers to a heterogeneous group of 
high-grade carcinomas that feature cells lacking distinct histological or cytological 
evidence of any of the more specifically differentiated neoplasms.
Large cell carcinoma: Composed of large, monotonous rounded or overtly 
polygonal-shaped cells with abundant cytoplasm.
Small cell carcinoma: Cells are usually round and are less than approximately 3 
times the diameter of a resting lymphocyte and little evident cytoplasm. Occasionally, 
small cell malignancies may themselves have significant components of slightly 
polygonal and/or spindle-shaped cells (Bermann, 2004b, Travis et al., 2004).
There are a large number of rare subtypes of anaplastic, undifferentiated carcinoma. 
Some of the more well known include the lesions containing pseudo-sarcomatous
components: spindle cell carcinoma (containing elongated cells resembling connective 
tissue cancers), giant cell carcinoma (containing huge, bizarre, multinucleated cells), and 
sarcomatoid carcinoma (mixtures of spindle and giant cell carcinoma). Pleomorphic 
carcinoma contains spindle cell and/or giant cell components, plus at least a 10% 
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component of cells characteristic of more highly differentiated types (i.e. adenocarcinoma 
and/or squamous cell carcinoma). Very rarely, tumors may contain individual
components resembling both carcinoma and true sarcoma, including carcinosarcoma and 
pulmonary blastoma (Travis et al, 2004)). Although tumors can arise in  almost any
tissue, the frequent organ sites of carcinoma are
 Lung: Carcinoma comprises >98% of all lung cancers.
 Breast: Nearly all breast cancers are ductal carcinoma.
 Prostate: The most common form of carcinoma of the prostate is adenocarcinoma.
 Colon and rectum: Nearly all malignancies of the colon and rectum are either 
adenocarcinoma or squamous cell carcinoma.
 Pancreas: Carcinoma is almost always of the adenocarcinoma type and is highly 
lethal.
Some carcinomas are named for their or the putative cell of origin, (e.g. hepatocellular 
carcinoma, renal cell carcinoma).
Cancer and the Immune System
The origins and progress of cancer immunology has been reviewed in depth, 
highlighting the development of ideas from Ehrlich and Medawar through to the cancer 
immune surveillance hypothesis of Burnet and into the era of cellular and molecular 
immunology (Dunn et al., 2002; Kaufmann, 2008). The immune system works essentially 
by discriminating self from non-self. Non-self is discriminated from self by fundamental 
differences in biochemistry, such as the arrangement of carbohydrate residues on 
glycoproteins or the absence of methylated cytosine residues in DNA. These differences 
are detected by the numerous pattern receptors, which are a hallmark of the innate 
immune system. These pattern receptors include the Toll-like receptors (O’Neill, 2008). 
The activation of innate immunity leads to the efficient priming of adaptive immune 
responses mediated by B and T cells. These cells carry antigen receptors and, through
education and cooperation, can distinguish self from non-self antigen and trigger 
subsequent events. However, tumour cells are self in origin and their biochemistry and 
behaviour differs only subtly from their healthy counterparts and thus, requires the 
detection of altered self. There is now a substantial body of data to show that innate and 
acquired immune responses to tumours do exist and that a multitude of immune cell types 
and their associated molecules are involved in detecting and eliminating tumours. 
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Immunity to infection and tumour immunity share a common ‘dark side’, that of immune 
evasion. It is a sad fact that, by the time a patient presents with a clinically detectable 
tumour, the tumour has already successfully evaded cancer immune surveillance 
mechanisms and is living alongside the immune system. Indeed, the immune system 
places strong selective pressure on tumours (and pathogens). Ultimately, the rare tumour 
cells that have mutations in the pathways that allow immune detection, elimination and 
evasion, the phenomenon of Immunoediting, (Figure B) are the cells that survive, 
proliferate and kill the patient (Teng et al., 2008). The goal behind many 
immunotherapeutic strategies is to tip the balance from tumour immune evasion to a 
productive anti-tumour response.
Figure B: Immune evasion and Inflammation (important components of 
Immunoediting) as Cancer Hallmarks. (from Hanahan and Weinberg, 2011).
Studies of the role of the cellular immune system in controlling cancer cells, 
promise to deliver not only fascinating insights into the immune system but also lay the 
foundation for future cellular immunotherapies. A better understanding of Tumor 
associated macrophages (TAM) and other myeloid-derived tumor-infiltrating cells as 
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pivotal players in the tumor microenvironment and as sources of Cancer-related 
inflammation (CRI) (Montovani et al., 2008) could certainly shed new light on the 
mechanistic understanding and development of efficient anticancer therapies. The present 
study was undertaken to understand the interaction of tumor cells of various origins, 
especially lung, with immune cells like monocytes/macrophages to establish new insights 
into such crosstalk.
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1.1 Tumor Immunology
Tumor immunology is the study of interactions between the immune system and 
cancer cells (also called tumors or malignancies). It is also a growing field of research 
that aims to discover innovative cancer immunotherapies to treat and retard progression 
of this disease. An important role of the immune system is to identify and 
eliminate tumors. The transformed cells of tumors express antigens that are not found on 
normal cells. The immune response, including the recognition of cancer-specific antigens
is of particular interest in this field as knowledge gained drives the development of new 
vaccines and antibody therapies. To the immune system, these antigens appear foreign, 
and their presence causes immune cells to attack the transformed tumor cells. The 
antigens expressed by tumors have several sources (Obeid et al., 2007) some are derived 
from oncogenic viruses like human papillomavirus, which causes cervical cancer
(Zitvogel et al., 2004) while others are the organism's own proteins that occur at low 
levels in normal cells but reach high levels in tumor cells. The main response of the 
immune system to tumors is to destroy the abnormal cells using killer T cells, sometimes 
with the assistance of helper T cells. Tumor antigens are presented on MHC class I 
molecules of DCs’ and Macrophages in a similar way to viral antigens. This allows killer 
T cells to recognize the tumor cell as abnormal. NK cells also kill tumorous cells in a 
similar way, especially if the tumor cells have fewer MHC class I molecules on their 
surface than normal; this is a common phenomenon with tumors. Sometimes antibodies 
are generated against tumor cells allowing for their destruction by the complement system.
Clearly, some tumors evade the immune system and go on to become cancers. Tumor 
cells often have a reduced number of MHC class I molecules on their surface, thus 
avoiding detection by killer T cells (Green et al., 2009). Some tumor cells also release 
products that inhibit the immune response; for example by secreting the cytokine TGF-β, 
which suppresses activity of macrophages and lymphocytes (Bierie and Moses, 2006). In
addition, immunological tolerance may develop against tumor antigens, so the immune 
system no longer attacks the tumor cells.
1.2 Immunosurveillance
There has been notable progress and accumulation of scientific evidence for the 
concept of cancer immunosurveillance and immunoediting based on (i) protection against 
development of spontaneous and chemically induced tumors in animal systems and (ii) 
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identification of targets for immune recognition of human cancer (Dunn et al, 2004).
Cancer immunosurveillance is a theory formulated in 1957 by Burnet and Thomas, who 
proposed that lymphocytes act as sentinels in recognizing and eliminating continuously 
arising, nascent transformed cells (Dunn et al., 2004; Smyth et al., 2006). Cancer 
immunosurveillance appears to be an important host protection process that inhibits 
carcinogenesis and maintains regular cellular homeostasis (Kim et al., 2007) It has also 
been suggested that immunosurveillance primarily functions as a component of a more 
general process of cancer immunoediting (Dunn et al., 2002). 
1.3 Immunoediting
Immunoediting is a process by which a person is protected from cancer growth 
and the development of tumour immunogenicity by their immune system. It has three 
main phases: elimination, equilibrium and escape (Kim et al., 2007; Dunn et al., 2004).
The elimination phase consists of the following four phases:
Figure 1.1: Mechanisms thought to be responsible for ‘immunoediting’ of tumor 
cells in the tumor microenvironment. (Whiteside, 2008)
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1.3.1 Elimination: Phase 1
The first phase of elimination involves the initiation of antitumor immune 
response. Cells of the innate immune system recognize the presence of a growing tumor 
which has undergone stromal remodeling, causing local tissue damage. This is followed 
by the induction of inflammatory signals which is essential for recruiting cells of the 
innate immune system (e.g. natural killer cells, natural killer T cells, macrophages and 
dendritic cells) to the tumor site (Figure 1.1). During this phase, the infiltrating 
lymphocytes such as the natural killer cells and natural killer T cells are stimulated to 
produce IFN-gamma (Zitvogel et al., 2006).
1.3.2 Elimination: Phase 2
In the second phase of elimination, newly synthesized IFN-gamma induces tumor 
death (to a limited amount) as well as promoting the production of chemokines CXCL10, 
CXCL9 and CXCL11. These chemokines play an important role in promoting tumor 
death by blocking the formation of new blood vessels. Tumor cell debris produced as a 
result of tumor death is then ingested by dendritic cells, followed by the migration of 
these dendritic cells to the draining lymph nodes. The recruitment of more immune cells 
also occurs and is mediated by the chemokines produced during the inflammatory process 
(Obeid et al., 2007).
1.3.3 Elimination: Phase 3
In the third phase, natural killer cells and macrophages transactivate one another 
via the reciprocal production of IFN-gamma and IL-12. This again promotes more tumor 
killing by these cells via apoptosis and the production of reactive oxygen and nitrogen 
intermediates. In the draining lymph nodes, tumor-specific dendritic cells trigger the 
differentiation of Th1 cells which in turn facilitates the development of CD8+ T cells.
1.3.4 Elimination: Phase 4
In the final phase of elimination, tumor-specific CD4+ and CD8+ T cells home to 
the tumor site and the cytolytic T lymphocytes then destroy the antigen-bearing tumor 
cells which remain at the site.
1.3.5 Equilibrium and Escape
Tumor cell variants which have survived the elimination phase enter the equilibrium 
phase. In this phase, lymphocytes and IFN-gamma exert a selection pressure on tumor 
cells which are genetically unstable and rapidly mutating. Tumor cell variants which have 
acquired resistance to elimination then enter the escape phase. In this phase, tumor cells 
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continue to grow and expand in an uncontrolled manner and may eventually lead to 
malignancies (Figure 1.1). In the study of cancer immunoediting, knockout mice have 
been used for experimentation since human testing is not possible (Dunn et al., 2004)
Tumor infiltration by lymphocytes is seen as a reflection of a tumor-related immune 
response (Odunsi and Old, 2007). 
Figure1.2:  The Cells of the Tumor Microenvironment (Hanahan and Weinberg. 2011).
1.4 Cells in the tumor microenvironment
A tissue microenvironment of developing tumor is comprised of proliferating 
tumor cells, the tumor stroma, blood vessels, infiltrating inflammatory cells and a variety 
of associated tissue cells (Figure 1.2). It is a unique environment that emerges in the 
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course of tumor progression as a result of its interactions with the host. It is created by 
and at all times shaped and dominated by the tumor, which orchestrates molecular and 
cellular events taking place in surrounding tissues. Immune cells present in the tumor 
include those mediating adaptive immunity, T-lymphocytes, dendritic cells (DC) and 
occasional B cells, as well as effectors of innate immunity, macrophages, 
polymorphonuclear leukocytes and rare natural killer (NK) cells (Whiteside, 2007). 
1.4.1 Natural Killer (NK) Cells
NK cells, which mediate innate immunity and are rich in perforin- or granzyme-
containing granules, are conspicuously absent from most tumor infiltrates or even pre-
cancerous lesions (Whiteside et al., 1998). Although NK cells represent ‘the first line’ of 
defense against pathogens (Lanier, 2003) and mediate potent antitumor cytotoxicity in 
vitro, in tumor milieu, they are infrequent, despite the fact that tumor cells frequently
downregulate expression of HLA antigens and are enriched in MICA and MICB 
molecules (Chang et al., 2005). These features make the tumor susceptible to NK cell-
mediated cytotoxicity (Lee et al., 2004), and their paucity in tumor infiltrates may be an 
example of the evasion mechanism preventing NK-cell recruitment to the tumor site.
1.4.2 Tumor-infiltrating lymphocytes (TILs)
TILs, containing various proportions of CD3þCD4þ and CD3þCD8þ T cells, are 
usually a major component of the tumor microenvironment (Whiteside, 2007). Many of 
these T cells are specific for tumor-associated antigens, as indicated by clonal analyses 
(Miescher et al., 1987) and tetramer staining of CD8þ T cells isolated from human tumors
(Albers et al., 2005). In some tumors, for example, medullary breast carcinomas, 
infiltrating lymphocytes form lymph node-like structures suggesting that the immune 
response is operating in situ (Coronella et al., 2002). Also, TILs are a source of tumor-
specific lymphocytes used for adoptive transfers after expansion in IL-2-containing 
cultures (Zhou et al., 2004). TIL clones with the specificity to a broad variety of the
tumor-associated antigens can be outgrown from human tumors, confirming that immune 
responses directed not only at ‘unique’ antigens expressed by the tumor, but also at a 
range of differentiation or tissue-specific antigens, are generated by the host (Romero et 
al., 2006). Although accumulations of these effector T cells in the tumor might be 
considered as evidence of immune surveillance by the host, they are largely ineffective in
Review of Literature
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arresting tumor growth. Among CD4þ T cells present in the tumor, a subset of 
CD4þCD25high Foxp3þ cells is expanded (5–15% of CD3þCD4þ T cells in TIL) relative 
to their significantly lower frequency in the peripheral circulation of patients with cancer 
(Woo et al., 2001; Strauss et al., 2007). These cells are regulatory T cells (Treg) capable 
of suppressing proliferation of other T cells in the microenvironment through contact-
dependent mechanisms or IL-10 and TGF-b secretion. They come in different flavors (for
example, nTreg, Tr1) and are a characteristic feature of the microenvironment in human 
tumors (Bergmann et al., 2007; Strauss et al., 2007).
1.4.3 Macrophages (MФ)
Macrophages present in tumors are known as tumor associated macrophages or 
TAMs. Paradoxically, Macrophages can promote tumor growth (Pollard, 2004) when 
tumor cells send out cytokines that attract macrophages, which then generate cytokines 
and growth factors that nurture tumor development. In addition, a combination of hypoxia 
in the tumor and a cytokine produced by macrophages induces tumor cells to decrease 
production of a protein that blocks metastasis and thereby assists spread of cancer cells.
They are re-programmed to inhibit lymphocyte functions through release of inhibitory 
cytokines such as IL-10, prostaglandins or reactive oxygen species (ROS) (Mantovani et 
al., 2005; Martinez et al., 2009). We discuss these cells in detail later.
1.4.4 Dendritic Cells
DCs are terminally differentiated myeloid cells that specialize in antigen 
processing and presentation. DCs differentiate in the bone marrow from various pro-
genitors (Steinmann, 1991, Vermi et al., 2011). Monocytes are the major precursors of 
DCs in humans (Vermi et al., 2011; Lin et al., 2010). Two major subsets of DCs are 
currently recognized: conventional DCs (cDCs) and plasmacytoid DCs (pDCs). Although 
these cells share some common progenitors, their differentiation is controlled by distinct 
genetic programmes and they have different morphologies, markers and functions (Vermi 
et al., 2011; Shurin et al., 2006). The centrepiece of DC biology is the concept of 
functional activation and maturation in response to ‘dangerous’ stimuli. Differentiated 
DCs reside in tissues as ‘immature’ cells that actively take up tissue antigens but are poor 
antigen presenters and do not promote effector T cell differentiation. Only functionally 
activated DCs can effectively stimulate immune responses. DCs are activated in response 
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to stimuli associated with bacteria, viruses or damaged tissues; such stimuli are 
commonly referred to as pathogen-associated molecular patterns (PAMPs) and damage-
associated molecular patterns (DAMPs). 
The fact that cancer can have profound effects on the function of DCs has been 
known for quite some time now. It is established that DCs in tumour-bearing hosts do not 
adequately stimulate an immune response, and this potentially contributes to tumour eva-
sion of immune recognition. Evidence from numerous studies strongly indicates that 
abnormal myelopoiesis is the dominant mechanism responsible for DC defects in cancer 
(Shurin, 2012; Lotza, 1997). This abnormal differentiation produces at least three main 
results: decreased production of mature functionally competent DCs; increased 
accumulation of immature DCs at the tumour site; and increased production of immature 
myeloid cells (Lin et al., 2010; Shurin, 2012). In recent years, multiple clinical studies 
have confirmed the findings of earlier studies and have indicated that there is a decreased 
presence and defective functionality of mature DCs in patients with breast, non-small cell 
lung, pancreatic, cervical, hepatocellular or prostate cancer, or glioma (Poppena et al., 
1983; Nestor and Cochran, 1987; Lijuna et al., 2012). 
Some DCs in tumour-bearing hosts actively suppress T cell function, and both 
phenotypically immature and phenotypically mature DCs may be conditioned by the 
environment to support immune tolerance or immunosuppression (Lin et al., 2010; 
Shurin, 2012). MHC-II+CD11b+CD11c+ tumour-infiltrating mouse DCs have been 
shown to suppress CD8+ T cells and antitumour immune responses through arginase 1 
(ARG1) production (Shrin, 2012; reichert et al., 2001) , an immunosuppressive 
mechanism previously attributed only to mouse tumour-associated macrophages (TAMs) 
and MDSCs . Human lung tumour cells can convert mature DCs into TGFβ-producing 
cells, and mouse lung cancer can drive DCs to express high levels of IL-10, nitric oxide, 
VEGF and ARG1 (Ladanyi et al., 2007; Sehrama et al., 2001; Reichert et al, 2001). 
1.4.4 Myeloid suppressor cells (MSC)
MSC accumulating in human tumors are CD34þCD33þCD13þCD15(+) bone 
marrow-derived immature dendritic cells, an equivalent to CD11bþ/ Gr1þ cells in mice 
(Serafini et al., 2006). They promote tumor growth and suppress immune cell functions
through copious production of an enzyme involved in L-arginine metabolism, arginase-1, 
which synergizes with iNOS to increase superoxide and NO production, blunting 
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lymphocyte responses (Ochoa et al., 2007) and by induction of iNOS in surrounding cells 
(Tsai et al., 2007). Relatively little is known about human MSC. A report describes 
expansion of CD14þHLA-DR+low myeloid-derived cells exerting immune suppression 
through TGF-b production in the peripheral circulation of patients with metastatic
melanoma treated with GM-CSF-based vaccines.
Polymorphonuclear leukocytes are infrequently seen in infiltrates of human 
tumors, with the exception of nests of eosinophils that may be present in association with 
tumor cells in various squamous cell tumors, for example. In contrast, granulocytes tend 
to be a major cellular component of many murine tumor models (Loukinova et al., 2000). 
This disparity may be because of a different nature of infiltrates, which in humans are
chronic rather than acute. Acute cellular responses may be long gone by the time human 
tumors are diagnosed, biopsied and examined.
1.5 Cancer and Monocytes/Macrophages
The tumor mass is undoubtedly a multifaceted show, where different cell types, 
including neoplastic cells, fibroblasts, endothelial, and immune-competent cells, interact 
with one another continuously. Macrophages represent up to 50% of the tumor mass, and 
they certainly operate as fundamental actors. Macrophages constitute an extremely 
heterogeneous population; they originate from blood monocytes, which differentiate into 
distinct macrophage types, schematically identified as M1 (or classically activated) and 
M2 (or alternatively activated) (Gordon, 2003; Montovani, 2002). It is now generally 
accepted that TAM have an M2 phenotype and show mostly pro-tumoral functions, 
promoting tumor cell survival, proliferation, and dissemination (Gordon and Taylor, 
2005; Montovani, 2002). High levels of TAM are often, although not always, correlated 
with a bad prognosis, and recent studies have also highlighted a link between their 
abundance and the process of metastasis (). Macrophage infiltration was studied along 
tumor carcinogenesis in a mouse model of pancreatic cancer induced by the expression of 
oncogenic KrasG12D. Macrophage infiltration began very early during the preinvasive 
stage of disease and increased progressively (Lin, 2001). Moreover, gene-modified mice 
and cell-transfer experiments have confirmed the pro-tumor function of myeloid cells and 
of their effector molecules. On the other hand, low macrophage infiltration into the tumor 
mass correlates with the inhibition of tumor growth and metastasis development in 
different animal models (Wyckoff et al, 2007; Lin et al, 2006; Hiraoka, 2008). Lin et al. 
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demonstrated that when MMTV-PyMT mice, which spontaneously develop mammary 
tumors, were crossed with mice lacking monocytes/macrophages (op/op), the tumor 
growth and spread were reduced significantly. Accordingly, when cocultured with tumor 
cells, macrophages secrete substances that stimulate tumor cell proliferation. This 
countersense in which cells of the immunological system work against self is the result of 
several refined tumor capabilities to mould immature cells and to suppress anticancer cell 
activity (Pollard, 2009). Within the tumor mass, another myeloid cell population defined 
as MDSCs characterized by immune suppressive activity by being able to suppress T cell 
blastogenesis in tumor-bearing hosts has also been identified (Galina et al., 2006; Bronte 
et al., 2001; Sica and Bronte, 2007).
1.5.1 Dr. Jekyll and Mr. Hyde: The Macrophage Heterogeneity in Inflammation and 
Immunity
Blood monocytes are not fully differentiated cells and are profoundly susceptible 
to several environmental stimuli. When recruited into peripheral tissues from the 
circulation, monocytes could differentiate rapidly in distinct, mature macrophages and 
exert specific immunological functions. M-CSF is the main regulator of the survival, 
proliferation, and differentiation of mononuclear phagocytes, and many studies have also 
identified a role in the subsequent polarization phase for this factor (Gordon, 2003; 
Condeelis and Pollard, 2006). Macrophages can be divided schematically into two main 
classes in line with the Th1/Th2 dichotomy (Figure 1.3). M1 macrophages (classically 
activated cells) originate upon encounter with IFN-γ and microbial stimuli such as LPS 
and are characterized by IL-12 high and IL-23 production and consequent activation of 
polarized type-I T-cell response (Pixley and Stanley, 2004; Pollard, 2009), cytotoxic 
activity against phagocytozed microorganisms and neoplastic cells, expression of high 
levels of RO-I, and good capability as APCs. In general, M1 macrophages act as soldiers: 
they defend the host from viral and microbial infections, fight against tumors, produce 
high amounts of inflammatory cytokines, and activate the immune response (Martinez et 
al., 2009; Goerdt et al., 1999). On the other hand, distinct types of M2 cells differentiate 
when monocytes are stimulated with IL-4 and IL-13 (M2a), with immune 
complexes/TLR ligands (M2b), or with IL-10 and glucocorticoids (M2c) (Pollard, 2009; 
Mantovani et al., 2005). Hallmarks of M2 macrophages are IL-10high IL-12low IL-1ra high
IL-1 decoyRhigh production, CCL17 and CCL22 secretion, high expression of mannose, 
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scavenger and galactose-type receptors, poor antigen-presenting capability and wound-
healing promotion. M2 cells are workers of the host: they promote scavenging of debris, 
angiogenesis, remodeling and repair of wounded/damaged tissues. Of note, M2 cells 
control the inflammatory response by down-regulating M1-mediated functions (Martnez 
et al., 2009; Mantovani et al., 2005). In addition, M2 macrophages are competent effector 
cells against parasitic infections. The loss of equilibrium of M1 and M2 cell number may 
lead to pathological events: an M1 excess could induce chronic inflammatory diseases, 
whereas an uncontrolled number of M2 could promote severe immune suppression 
(Martinez et al., 2009) (Figure 1.3).
Figure 1.3: Polarization of macrophage function (Adapted from Allavena et al., 2009)
Review of Literature
17
1.5.2 TAM-Tumor Associated Macrophage
TAMs originate from blood monocytes recruited at the tumor site (Pollard, 2004)
by molecules produced by neoplastic and by stromal cells (Figure 1.4). The chemokine 
CCL2, earlier described in 1983 as a tumor-derived chemotactic factor, is the main player 
in this process (Allavena et al., 2008c; Pollard, 2004) and experimental and human 
studies correlate its levels with TAM abundance in many tumors, such as ovarian, breast 
and pancreatic cancer (Allavena et al., 2008c). TAM themselves produce CCL2, 
suggesting the action of an amplification loop and anti-CCL2 antibodies combined with 
other drugs have been considered as an anti-tumor strategy (Colombo and Mantovani, 
2005). Other chemokines involved in monocyte recruitment are CCL5, CCL7, CXCL8, 
and CXCL12, as well as cytokines such as VEGF, PDGF and the growth factor M-CSF 
(Balkwill, 2004; Allavena et al., 2008c). Moreover, monocytes could be attracted by 
fibronectin, fibrinogen and other factors produced during the cleavage of ECM proteins 
induced by macrophage and/ or tumor cell-derived proteases (Denardo et al., 2008).
When monocytes (then macrophages) reach the tumor mass, they are surrounded 
by several signals able to shape the new cells as needed by the tumor (Figure 1.4). As far 
as they have been studied, TAM resemble M2-polarized macrophages (Mantovani et al., 
2002; Pallard, 2004; Talmadge et al., 2007)]. This preferential polarization is a result of 
the absence of M1- orienting signals, such as IFN-γ or bacterial components in the tumor, 
as well as the expression of M2 polarization factors. In particular, the infiltration of Th2 
lymphocytes (driven by Th2- recruiting chemokines such as eotaxins) has been reported 
in many tumors, and they are a fundamental source of IL-4 and IL-13 cytokines (Nevala 
et al., 2009; Cheadle et al., 2007). Moreover, neoplastic cells, fibroblasts, and Tregs 
produce TGF-β and IL-10. Incoming monocyte differentiation is also influenced by their 
localization within the tumor mass; for instance, in tumors, there is an established 
gradient of IL-10. This factor switches monocyte differentiation toward macrophages 
rather than DC (Cheadle et al., 2007; Li and Flavell, 2008)], and thus, as observed in 
breast cancer and in papillary carcinoma of the thyroid, TAM are present throughout the 
tissues, whereas DC are present only in the periphery (Scarpino et al., 2000).
The M2 polarization of TAM has also been demonstrated by studying their 
transcriptional profiling. Recent investigations noticed the up-regulation of many M2-
associated genes such as CD163, Fc fragment of IgG, C-type lectin domains and heat 
shock proteins (Biswas et al., 2006; Sakai et al., 2008; Beck et al., 2009). In the tumor 
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milieu, TAM carry on their pro-neoplastic role by influencing fundamental aspects of 
tumor biology; they produce molecules that affect neoplastic cell growth directly (e.g., 
EGF), enhance neoangiogenesis, tune inflammatory responses and adaptive immunity and 
catalyze structural and substantial changes of the ECM compartment (Pollard, 2009; 
Mantovani et al., 2008; Allavena et al., 2008). Another hallmark of TAM is their 
tendency to accumulate into necrotic regions of tumors, characterized by low oxygen 
tension (Lewis and Murdoch, 2005). This preferential localization is regulated by tumor 
hypoxia, which induces the expression of HIF-1-dependent molecules (VEGF, CXCL12, 
and its receptor CXCR4) that modulate TAM migration in avascular regions (Talks et al., 
2000; Schioppa et al., 2003)]. HIF-1 also regulates myeloid cell-mediated inflammation 
in hypoxic tissues (Cramer et al., 2003) and this link between hypoxia and innate 
immunity was confirmed recently, showing that HIF-1 is also regulated transcriptionally 
by NF-κB (Rius et al., 2008). Biochemical studies have identified the transcription factor 
NF-κB as a master regulator of cancer-related inflammation in TAM and in neoplastic 
cells. Constitutive NF-κB activation is indeed observed often in cancer cells and may be 
promoted by cytokines (e.g., IL-1 and TNF) expressed by TAM or other stromal cells, as 
well as by environmental cues (e.g., hypoxia and ROI) or by genetic alterations (Karin, 
2006; Mantovani et al., 2008; Aggarwal, 2004). NF-κB induces several cellular 
modifications associated with tumorigenesis and more aggressive phenotypes, including 
self-sufficiency in growth signals, insensitivity to growth inhibition, resistance to 
apoptotic signals, angiogenesis, migration and tissue invasion (Pikarsky et al., 2004; 
Greten et al., 2004; Naugler and Karin, 2008). In a mouse model of colitis-associated 
cancer, the myeloid-specific inactivation of the Iκβ kinase inhibited inflammation and 
tumor progression, thus providing unequivocal genetic evidence for the role of 
inflammatory cells in carcinogenesis. On the other hand, in established, advanced tumors, 
where inflammation is typically smoldering (Balkwill et al., 2005), TAM usually have 
defective and delayed NFκ-B activation in response to different proinflammatory signals 
(e.g., expression of cytotoxic mediators such as NO, cytokines, TNF-α, and IL-12) 
(Biswas et al., 2006; Sica et al., 2000; Torroella-Kouri et al., 2005). These observations 
are in apparent contrast with a pro-tumor function of inflammatory reactions expressed by 
TAM. This discrepancy may reflect a dynamic change of the tumor microenvironment 
along tumor progression. In early stages of carcinogenesis, innate responses 
(inflammatory reactions) are indispensable for the activation of effective surveillance by 
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adaptive immunity (Dunn et al., 2004; Smyth et al., 2006) but on the other hand, are also 
likely to promote tumor development. In late stages of neoplasia, the defective NF-κB 
activation of TAM is insufficient to drive and sustain a potential anti-tumor immune 
response of the host. Evidence suggests that p50 homodimers (negative regulators of NF-
κB) are abundant in TAM and are responsible for its defective activation (Saccani et al., 
2006). As a matter of fact, TAM exert strong immune suppressive activity, not only by 
producing IL-10 but also by the secretion of chemokines (e.g., CCL17 and CCL22), 
which preferentially attract T cell subsets devoid of cytotoxic functions such as Treg and 
Th2 (Balkwill, 2004; Mantovani et al., 2004). In normal macrophages, these chemokines 
are inducible by IL-4, IL-10, and IL-13, thus amplifying an M2-mediated immune-
suppressive loop. In addition, TAM secrete CCL18, which recruits naı¨ve T cells by 
interacting with an unidentified receptor (Schutyser et al., 2002). Attraction of naı¨ve T 
cells in a microenvironment characterized by M2 cells and immature DC is likely to 
induce T cell anergy.
1.5.3 TAM and Angiogenesis
Angiogenesis is sustained by different mediators produced by neoplastic and by 
stromal cells. TAM release growth factors such as VEGF, PDGF, TGF-β and members of 
the FGF family (Mantovani et al., 2002; Bingle et al., 2002), and the proangiogenic role 
is highlighted by the correlation between their high numbers and high vascular grades in 
many tumors such as glioma, squamous cell carcinoma of the esophagus, breast, bladder 
and prostate carcinoma (Bingle et al., 2002). TAM secrete the angiogenic factor 
thymidine phosphorylase, which in vitro promotes endothelial cell migration (Lin et al., 
2006) and they also produce several angiogenesis modulating enzymes such as MMP-2, 
MMP-7, MMP-9, MMP-12, and cyclooxygenase-2 (Lin et al., 2006; Bingle et al., 2002). 
1.5.4 TAM: Invasion and Metastasis 
Metastasis unquestionably represents a crucial phase of neoplastic diseases and 
develops when tumor cells acquire specific capabilities to leave the primary tumor, 
invade the surrounded matrix, reach through blood or lymphatic vessels’ distant sites, 
settle down and grow. As a result of its complexity, this process has yet to be analyzed 
further, but several lines of evidence have already identified a tight link between this 
process and TAM, which produce inflammatory cytokines likely active on the 
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dissemination stage. The intense cross-talk between macrophages and neoplastic cells 
guarantees the continuous process of matrix deposition and remodeling, which facilitates 
tumor growth and invasion of the surrounding tissues (Figure 1.4). The high tissue 
remodelling activity of TAM is summarized by Dvorak’s definition: “Tumors are never 
healing wounds” (Dvorak, 1986; Codeelis and Pollard, 2006). TAM co-operate on tumor 
dissemination by promoting invasion characteristics of malignant cells and also by 
making easier their movement by a direct action on the tumor microenvironment 
(Hagemann et al., 2004). In particular, one of the main factor involved significantly is 
TNF-α: coculture of neoplastic cells with macrophages enhances invasiveness of 
malignant cells through TNF-dependent MMP induction in macrophages (Hagemann et 
al., 2004). TAM produce IL-1, and Giavazzi and colleagues (Giavazzi et al., 1990) 
demonstrated the IL-1-induced augmentation of metastasis development in a mouse 
melanoma model. In a genetic model of breast cancer growing in monocyte deficient 
mice, the tumors developed normally but in the absence of the macrophage-produced 
EGF, were unable to form pulmonary metastasis (Pollard, 2008). 
1.5.6 TAM and Anti-Cancer Therapies
It is underlined how TAM favor neoplastic cells during tumor development and 
invasion and spread to distant sites. Thus, it is easy to gather that these cells may certainly 
be considered as an attractive target for novel anti-cancer therapies. If we block 
macrophages, will we actually disturb tumor progression in human patients? Within a 
tumor, a heterogeneous microenvironment differentially influences infiltrated 
macrophages, and this shows clearly the necessity of identifying common TAM targets 
for the synthesis of new therapeutic molecules (Zitvogel et al., 2008). Obviously, the best 
target would be a protein expressed or overexpressed only by TAM and neither by 
resident macrophages of distant, healthy tissues nor by M1 cells, which are important to 
face pathogens and could take part in anti-cancer actions. Several “anti-macrophage” 
approaches are under evaluation currently. Interesting observations come from studies 
performed with chemokines and chemokine receptors as anti-cancer targets (Zitvogel et 
al., 2008; Bingle et al., 2002). 
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Figure 1.4: Overview of TAM, which originate from blood monocytes recruited at 
the tumor site by molecules produced by neoplastic and by stromal cells. (Adapted 
from Allavena et. al., 2009).
Macrophages have also been used to enhance the immune response or to 
potentiate chemotherapy specificity. Carta and colleagues (Carta et al., 2001) engineered 
a murine macrophage cell line that strongly augmented the production of IFN-γ. The 
delicate balance between M1 and M2 cells is a fundamental aspect in anti-cancer 
treatment also. Several studies have shown that the activation of TLRs (for instance, 
TLR9) stimulates M1-polarized macrophage responses by inducing the activation of a 
proinflammatory program (Krieg, 2006). 
In general, the restoration of an M1 phenotype in TAM may provide a therapeutic 
benefit by promoting antitumor activities. SHIP1-deficient mice showed a skewed 
development toward M2 macrophages, and thus, pharmacological modulators of this 
phosphatase are under investigation currently (Ong et al., 2007; Guiducci et al., 2005). 
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Interestingly, a contribution of the immune system to the anti-tumor effects of 
conventionally used chemotherapy treatments has been suggested. Cells of the innate 
immunity can be activated by proteins secreted by dying cells— damage associated 
molecular patterns (Zitvogel et al., 2008; Green et al., 2009). 
1.6 Cancer Related Inflammation (CRI)
The association between cancer and inflammation dates back to Rudolf Virchow
(1863) when he noticed the presence of leukocytes in neoplastic tissues (Balkwill and 
Montovani, 2001). Studies have identified two main pathways linking inflammation and 
cancer: an intrinsic and an extrinsic pathway (Coussens and Werb, 2002). The first one 
includes genetic alterations that lead to inflammation and carcinogenesis, whereas the 
second one is characterized by microbial/ viral infections or autoimmune diseases that 
trigger chronic inflammation in tissues associated with cancer development. Both 
pathways activate pivotal transcription factors of inflammatory mediators (e.g., NF-κB, 
STAT3, and HIF-1) and inflammatory cells (Hagemann et al., 2008; Kin and Karin,
2007; Karin, 2006).
Inflammatory cells like DCs, Macrophages, Neutrophils etc. present in the tumor 
microenvironment either contribute to tumor progression or actively interfere with its 
development (Figure 1.5). It is clear now that the former takes precedence, largely 
because the tumor generally proceeds to establish mechanisms responsible for its 
‘immune evasion’ or escape from the immune intervention (Talmadge et al., 2007). The 
tumor not only manages to escape from the host immune system, but it effectively
contrives to benefit from infiltrating cells by modifying their functions to create the 
microenvironment favourable to tumor progression. To this end, immune cells infiltrating 
the tumor together with fibroblasts and extracellular matrix forming a scaffold supporting 
its expansion, contribute to establish an inflammatory milieu that nourishes the tumor and 
promotes its growth. Inflammation is a salutary response to insult or injury and an 
important part of innate immunity; however, chronic inflammation has been linked with 
the development of cancer. Individuals with ulcerative colitis, a chronic inflammatory 
disease of the colon, have a 10-fold higher likelihood of developing colorectal carcinoma. 
Similarly, inflammatory conditions of the liver, such as chronic hepatitis and cirrhosis, 
are well established risk factors for the development of hepatocellular carcinoma (Karin, 
2006). 
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Chronic Inflammatory conditions have been observed in association with tumor 
incidence, tumor progression and detrimental prognosis in human cancer patients. It is 
still early to understand the molecular mechanisms of how and why tumors occur more 
frequently in an inflammatory microenvironment or in an inflammation-plagued host. 
Pro-inflammatory cytokines are not surprisingly at the crossroad of this deregulation. 
Several of these cytokines are highly expressed in human cancers and do alter the
immune response in ways that are simultaneously beneficial to tumor growth (Kin and 
Karin, 2007). It is tempting to speculate that the observed derailing of antitumor 
immunity into an inflammatory response is at its core, a defensive strategy of the tumor, 
selected for independently of the tumor cell transformation. Alternatively, it might be the 
mere result of, and the default reaction to, the expression of transforming oncogenes 
within the tumor cell. Third, the presence of mutant cell clones in an inflamed and 
regenerating tissue could simply be an unfortunate coincidence. Here, the tumor cell 
would take advantage of the improved cytokine mediated growth conditions for the 
nascent tumor, whereas the same cytokines inhibit the immune-mediated tumor 
surveillance and tumor cell elimination (Dunn et al., 2002).
Recent research has highlighted an important role for inflammation in cancer from 
the perspective that innate immune cells, such as macrophages, drive malignant 
progression through the production of proinflammatory mediators such as tumor necrosis 
factor (TNF) and interleukin (IL)-6 (Greten et al., 2004; Maeda et al., 2003; Rakoff-
Nahoum et al., 2004). In the context of gastric or colon cancer, the stimulus for activation 
of the innate immune cells may be provided by chronic infection with Helicobacter pylori 
or commensal bacteria that access the resident inflammatory cells through a breakdown in 
the barrier function of the epithelium during carcinogenesis. In cervical cancer and 
hepatocellular carcinoma, chronic infection with human papilloma virus (HPV) and 
hepatitis C virus (HCV), respectively, are clearly linked with carcinogenesis. The study 
by Naugler et al., using a mouse model of chemically induced liver cancer, suggests cell 
injury may also lead to the release of endogenous factors that activate innate immune 
cells. These authors showed that dead hepatocytes activate liver macrophages (Kupffer 
cells) through the molecule MyD88, which is an essential adaptor for Toll like receptor 
(TLR) signalling (Lawrence et al., 2007; Naugler and Karin, 2008). The TLRs are 
pathogen recognition molecules that are hard-wired to trigger activation of innate 
immunity upon recognition of pathogen-associated molecular patterns (PAMPs). TLRs 
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Figure 1.5: The Multifaceted Role of Inflammation in Cancer:
Inflammation acts at all stages of tumorigenesis. It may contribute to tumor initiation through mutations, 
genomic instability, and epigenetic modifications. Inflammation activates tissue repair responses, induces 
proliferation of premalignant cells, and enhances their survival. Inflammation also stimulates angiogenesis, 
causes localized immunosuppression, and promotes the formation of a hospitable microenvironment in 
which premalignant cells can survive, expand, and accumulate additional mutations and epigenetic changes. 
Eventually, inflammation also promotes metastatic spread. Mutated cells are marked with ‘‘X.’’ Yellow, 
stromal cells; brown, malignant cells; red, blood vessels; blue, immune and inflammatory cells. EMT, 
epithelial-mesenchymal transition; ROS, reactive oxygen species; RNI, reactive nitrogen intermediates.
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have an important role in driving the inflammatory response but also in priming adaptive 
immunity through the activation and maturation of antigen presenting cells, including 
dendritic cells (DCs) and macrophages. Apetoh et al. (2007) have revealed an interesting 
role of inflammation and TLR signaling in cancer therapy.
The major antigen-presenting cells present in tumors are macrophages, which in 
certain cases may account for as much as 50% of the tumor mass; however, often it is not 
possible to detect an adaptive immune response to tumor antigens. There is increasing 
evidence that tumor associated macrophages (TAMs) express an immunosuppressive 
phenotype and display several protumoral functions, including promotion of angiogenesis 
and matrix remodelling (Balkwill et al., 2005; Pollard, 2004). Although usually rare, DCs 
have been detected in several tumor types, but DCs in tumors have been shown to express 
an immature phenotype and therefore to have low immunostimulatory properties
(Mantovani et al., 2002). Both DCs and macrophages have the ability to pick up tumor
antigens for crosspresentation on MHC class I molecules (Ardavin et al., 2004). 
However, the phenotype of TAMs and intratumoral DCs has been suggested to promote 
tolerance through production of immune- suppressive factors rather than prime a 
protective immune response (Mantovani et al., 2002).
1.7 Cytokines: The mediators of cancer and immune cell interplay
A solid body of evidence links increases in tumor incidence with inflammation. In
addition, clinical and experimental findings also link tumor progression to the 
upregulation of pro-inflammatory molecules, particularly during the late stages of cancer 
progression and during tumor cachexia (Balkwill et al., 2005). Several of the cytokines 
linked to tumorpromoting inflammation such as tumor necrosis factor-a (TNF-a), 
transforming growth factor-b (TGF-b), IL-6 and IL-23 are functionally linked to the 
newly discovered Th17 CD4þ helper cell lineage (Balkwill, 2004).
1.7.1 Dual role for TNF-α in cancer
Tumor necrosis factor-α is a trimeric cytokine produced by activated macrophages 
and pro-inflammatory T cells. TNF-α can stimulate both pro-and antiapoptotic signals in 
tumor cells, endothelial cells, macrophages and most other cells within the tumor 
microenvironment (Szlosarek et al., 2006). TNF-α as well as IL-1 are essential effector 
cytokines for the initiation and maintenance of chronic inflammation in mouse models of 
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immune-mediated disorders such as rheumatoid arthritis (Williams et al., 2000). The 
relevance of this pathway for human disease is best exemplified in the success of anti-
TNF-α therapies in inflammatory diseases (Feldmann and Maini, 2001). TNF-α also 
induces apoptosis in activated tumor-infiltrating T cells, and therefore may function to 
blunt the immune surveillance against tumors within the tumor itself. Although the pro-
apoptotic effects of TNF-α spiked interest in its therapeutic utility, it requires higher 
concentrations than therapeutically achievable (Mocellin et al., 2005). Most animal 
models and clinical studies revealed the pro-neoplastic functions of TNF-α rather than its
pro-apoptotic functions on tumor cells.
Tumor necrosis factor-a produced by tumor cells or inflammatory cells may 
promote tumor survival via the induction of antiapoptotic genes controlled by nuclear
factor-kB activation. Indeed, TNF-α has been demonstrated to promote tumorigenesis as 
TNF-α-deficient mice or mice treated with anti-TNF-α antibodies are largely protected 
from the chemical induction of skin papillomas (Moore et al., 1999; Scott et al., 2003). 
TNF-α may also directly contribute to neoplastic transformation by stimulating 
production of genotoxic reactive oxygen species and nitric oxide (Szlosarek et al., 2006).
In humans, higher concentrations of TNF-α are found in the serum of cancer patients 
compared to control subjects, and elevated TNF-α concentrations in the serum also 
correlate with decreased prognosis for the patients (Szlosarek and Balkwill, 2003). 
Finally, TNF-α is closely associated with tumor-induced cachexia, an inflammatory 
multiorgan failure in the late stage of cancer patients, and with the inflammatory
paraneoplastic syndromes associated with tumors like pancreatic cancer. Genetic 
polymorphisms conferring higher TNF-α production are associated with increased risk of 
a variety of human cancers (Szlosarek et al., 2006). Excitingly, renal cell cancer patient
treated in a phase II clinical study with anti-TNF-α antibodies experienced clinical 
benefits (Harrison et al., 2007).
1.7.2 Inflammation control by TGF-β
Another key regulator of inflammatory processes tightly associated with chronic 
inflammation and cancer is TGF-β. Although considered to be primarily 
antiinflammatory, TGF-β contributes to the inflammatory milieu of tumor mediators and 
cell types facilitating tissue remodeling as well as direct local suppression of antigen-
specific CD8-T cell function. Transforming growth factor-β is a pleiotropic cytokine that 
Review of Literature
27
exerts effects on most cell types in a tumor thereby simultaneously impacting 
immunological and non-immunological processes. TGF-β activates a heterodimeric
receptor pair of TGF-β receptors I and II (TbRI/II). Upon ligand binding, TbRI directly 
phosphorylates the transcription factors Smad2 and Smad3, which shuttle to the nucleus 
to induce transcription (Letterio, 2005). TGF-βb is released not only by a variety of cells 
in human and mouse tumors including macrophages, platelets and T cells (Kehrl et al., 
1986; Roberts et al., 1986), but also by the tumor cells themselves. Early in the 
development of cancer and in premalignant lesions, TGF-β plays a tumor suppressive 
function due to its inhibition of tumor cell growth. Genetic deletion of the TGF-β receptor 
in genetic mouse models for human cancer leads to increased tumor incidence and
progression (Bierie and Moses, 2006). Interestingly, ablation of TGF-β signaling in the 
tumor cells leads to an increased level of TGF-β in the tumor and increased number of 
TGF-β-producing CD11b+ GR-1+ myeloid cells in the tumor stroma (Yang et al., 2008).
However, most human tumors thrive in the presence of large amounts of TGF-β while 
retaining the TGF-β signaling pathways. The exception appears to be malignancies of the 
gastrointestinal tract where mutations in either the TGF-β receptor or the Smads render
the tumor cells insensitive to abundant TGF-β (Derynck et al., 2001). Autocrine TGF-β
regulation in tumor cells plays an important role during invasion, metastasis and 
epithelial–mesenchymal transition of tumor cells (Oft et al., 2002). In addition, many of 
the tumors promoting effects of TGF-β involve paracrine regulation of inflammation and 
tissue remodeling. TGF-β modifies the activities of fibroblasts, endothelial cells,
macrophages and T cells to engender an inflammatory milieu similar to chronic 
inflammatory diseases but deficient in cytotoxic cells such as CD8T cells and natural 
killer cells. TGF-β is one of the first proteins released from platelets after a vascular 
lesion, induces angiogenesis (Roberts et al., 1986) and is a potent chemoattractant for 
granulocytes and monocytes (Wahl et al., 1987; Brandes et al., 1991); TGF-β also limits 
the phagocytic and opsonizing activity of those innate responders. More importantly, 
although TGF-β promotes the development of Langerhans cells and dendritic cells from 
hematopoietic progenitors (Borkowski et al., 1996; Strobl et al., 1996), it inhibits the
maturation, antigen presentation and costimulation by both macrophages and dendritic 
cells (Li et al., 2006).
Such immature dendritic cells produce large amounts of TGF-β and might 
efficiently prime regulatory CD4 T cells (Treg). TGF-β is required for the development of
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Tregs, and TGF-β expression by Tregs is essential for their proliferation and function. 
Regulatory T cells are found in human tumors and their presence correlates again with a 
poorer prognosis (Curiel et al., 2004). In a new twist of the development of helper T-cell 
lineages, it has become clear that pro-inflammatory IL-17-producing Th17T cells share a 
common path with regulatory T cells. Although the presence of TGF-β favors a
regulatory fate of naive T cells, simultaneous presence of TGF-β and IL-6 fosters the 
differentiation of a proinflammatory T cell expressing IL-6 and IL-17 among other 
cytokines (Bettelli et al., 2006). Transforming growth factor-β not only restricts the
proliferation of naive CD4þ T cells by suppressing IL-2 production in T cells but also 
antagonizes both Th1 and Th2 effector differentiation (Li et al., 2006). At the same time, 
however, TGF-β protects T cells from apoptosis during T-cell expansion and 
differentiation. In particular, TGF-β inhibits activation-induced cell death of T cells 
(Zhang et al., 1995). Polyclonal T-cell activation in mice using activating anti-CD3 
antibodies leads to widespread apoptosis of both CD4+ and CD8+ T cells in TGF-β1-/-
mice (Chen et al., 2001). Similar to helper T cells, CD8+ cytotoxic T cells are inhibited in
their proliferation and differentiation by TGF-β (Wrzesinski et al., 2007). TGF-β inhibits 
the expression of cytokines like interferon-γ (IFN-γ) and cytotoxic effector molecules 
such as perforin, and also the exocytosis of the cytotoxic granules (Li et al., 2006).
Moreover, when stimulated with both IL-6 and TGF-β, CD8T cells not only cease 
expression of IFN-γ and lose their cytotoxicity but are also induced to secrete IL-17 (Liu 
et al., 2007). IFN-γ induces major histocompatibility complex I in both dendritic cells and 
tumor cells; therefore, replacing IFN-γ with IL-17 in the tumor milieu might have severe 
consequences for immune recognition and surveillance.
1.7.3 The pro-inflammatory cytokine IL-6 promotes tumor growth
Interleukin-6 engages the heterodimeric receptor complex of glycoprotein 130 
(gp130) and IL-6 receptor-a (IL-6Ra). While gp130 is expressed in the signal receiving
cell, the IL-6Ra subunit can be either membrane bound or supplied as a soluble receptor
(sIL-6Ra) by an accessory cell, via a process known as trans-signaling (Rose-John et al., 
2006). IL-6 induces the phosphorylation of both STAT3 and STAT1. The involvement of 
both IL-6 and STAT3 in malignant cell survival and proliferation has been well 
documented in numerous experimental systems (Aggarwal et al., 2006; Rose-John et al., 
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2006). Through the activation of genes involved in cell cycle progression and suppression 
of apoptosis, IL-6 can directly protect tumor cells from apoptosis. IL-6 has also been 
shown to act as an autocrine growth factor for tumors (Baffet et al., 1991). IL-6 is 
essential in the initiation and maintenance of chronic inflammation of the colon (Atreya et 
al., 2000). Trans-signaling of IL-6 is similarly essential for the development of 
inflammation-induced colon tumors (Becker et al., 2004). Finally, antibody-mediated 
inhibition of IL-6 delays the development of chemically induced colitis-associated colon 
cancer (Becker et al., 2004). Interleukin-6 levels are elevated in the serum and tissue of 
cancer patients with multiple myeloma, renal cell, ovarian, colon, breast or prostate 
cancers. The IL-6 serum levels correlate negatively with the prognosis in breast and 
prostate cancer patients (Smith et al., 2001; Rao et al., 2006). IL-6Ra is highly expressed 
on tumor cells, with some evidence for shedding of the sIL-6Ra to stimulate trans-
signaling in cells not expressing IL-6Ra (Becker et al., 2004; Rose-John et al., 2006). IL-
6 may also be a cancer-predisposing genetic risk factor, with IL-6 promoter 
polymorphisms leading to higher IL-6 expression leading to a worse prognosis for colon 
cancer patients (Landi et al., 2003).
In combination with TNF-a, IL-6 stimulates the expansion and cytotoxicity of 
naive CD8T cells in vitro (Sepulveda et al., 1999); however, IL-6Ra has been shown to 
be downregulated upon activation in naïve and memory T cells (Betz and Muller, 1998), 
suggesting that its potential stimulatory effect on tumor-infiltrating effector lymphocytes 
may be lost. Recently, however, it has become clear that IL-6 together with TGF-b is
crucial for the induction of IL-17-producing Th17 helper cell lineage (Mangan et al., 
2006; Wilson et al., 2007). It remains to be tested how many of the effects of IL-6 in the 
regulation of tissue inflammation and cancer are dependent on the induction and
subsequent control of this T-cell lineage. Importantly, it has been shown that the pro-
inflammatory T helper cells continue to express both IL-17 and IL-6 (Becker et al., 2004; 
Langrish et al., 2005). In inflammatory disease models, deficiency of IL-17 ameliorates 
the disease, deficiency of both IL-6 or IL-23, a cytokine controlling the activity of Th17 
cells, protected animals from disease (Alonzi et al., 1998; Cua et al., 2003; Nakae et al., 
2003). While IL-6-deficient animals show a partial resistance to chemical-induced skin 
tumors (Ancrile et al., 2007); the absence of IL-23 renders animals completely protected 
from tumors (Langowski et al., 2006).
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1.7.4 Interleukin 10
Another cytokine that activates STAT3 is IL-10 (Moore et al., 2001)). However, 
the effects of IL-10 are dramatically opposed to those of IL-6, as IL-10 is 
immunosuppressive and anti-inflammatory (Allavena et al., 1998; Moore et al., 2001). 
IL-10 inhibits NF-kB activation through ill-defined mechanisms (Mocellin et al., 2001; 
Moore et al., 2001) and consequently inhibits the production of proinflammatory 
cytokines, including TNF-α, IL-6, and IL-12 (Vicari and Tinchieri, 2004). Given this, it is 
no wonder that IL-10 inhibits tumor development and progression. The most striking 
effects of IL-10 are seen in Il10–/– mice, which are more prone to colonic inflammation
and CAC when chronically infected with certain enteric bacteria, such as Helicobacter 
hepaticus (Akdis and Blaser, 2001). The mechanisms responsible for IL-10 inhibition of 
colitis are not completely clear but might be linked to its ability to counteract IL-12–
driven inflammation or its ability to inhibit NF-kB activation (Sato et al., 2011). Indeed, 
enhanced IL-12p40 production by immune cells is a key feature of colonic inflammation 
Suppression of TNF-α and IL-12 release by DCs and macrophages might also contribute 
to the antitumor activity of Tregs and IL-10 (Allavena et al., 1998; Moore et al., 2001). 
However, it is not clear how STAT3 activation by IL-10 results in an antitumor effect, 
whereas STAT3 activation by IL-6 is considered to be pro-tumorigenic. Studies also 
suggest that IL-10 possesses immunostimulatory activity that enhances antitumor 
immunity (Mocellin et al., 2004). Although IL-10 usually exerts antitumor activity, its 
biological effects are not all that simple, and consistent with its ability to activate STAT3, 
it might also promote tumor development. Direct effects of IL-10 on tumor cells that 
might favor tumor growth have been reported. For example, an IL-10 autocrine and/or
paracrine loop might have an important role in tumor cell proliferation and survival. IL-
10 has also been shown to modulate apoptosis and suppress angiogenesis during tumor 
regression (Sato et al., 2011). Expression of IL-10 in mammary and ovarian carcinoma 
xenografts inhibits tumor growth and spread (Sato et al., 2011). IL-10 has complex 
effects on tumor development. In many experimental systems, IL-10 is found to exert 
antitumor activity, but in other cases it can be pro-tumorigenic (Sato et al., 2011). These 
dramatically opposing effects of IL-10 might depend on interactions with either cytokines 
or factors found in the tumor microenvironment, as it is unlikely that IL-10 functions in 
isolation. A better understanding of IL-10 signaling is needed before its effects on tumor 
growth and antitumor immunity can be fully explained.
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1.7.5 Inflammation control by IL-23 and IL-12 in cancer
Interleukin-23 and IL-12 are closely related heterodimeric pro-inflammatory 
cytokines with similar structures, similar cellular sources and cellular targets but opposing 
functions. They are composed of a shared p40 subunit, structurally related to cytokine 
receptors, and a unique subunit, IL-23p19 or IL-12p35, structurally four-helix bundle 
cytokines (Kastelein et al., 2007). IL-12 uses the heterodimeric receptors IL-12Rb1 and
IL-12Rb2, whereas IL-23 activates IL-12Rb-1/IL-23R dimers (Parham et al., 2002). Like 
IL-12, IL-23 induces TYK2-and JAK2-mediated phosphorylation of the transcription 
factors STAT1, STAT3 and STAT5, the phosphorylation of STAT4 being to a lesser 
extent (Parham et al., 2002; Trinchieri, 2003). The receptors for both IL-12 and IL-23 are
primarily expressed on T, natural killer and natural killer T cells, with low levels present 
on monocytes, macrophages and dendritic cells. Both cytokines are produced primarily 
by activated antigen-presenting cells in response to bacterial products (Trinchieri et al., 
2003). Consequently, IL-12p40-deficient mice, lacking IL-12 and IL-23, are highly
susceptible to numerous bacterial, fungal and parasite infections including Salmonella, 
Citrobacter, Cryptococcus and Leishmania species (Bowman et al., 2006). For the 
response against most of these pathogens, IL-12- mediated responses are essential, 
whereas the IL-23 contribution is often only detected in the simultaneous absence of IL-
12 (Kastelein et al., 2007). Instant lethal doses of Klebsiella or Citrobacter, however, 
require IL-23-mediated host responses in mice (Happel et al., 2003; Mangan et al., 2006). 
Surprisingly, these susceptibilities have not been described for IL-12p40- or IL12Rb1-
deficient humans who suffer exclusively from mycobacterial and salmonella infection but 
show normal resistance to most other pathogens, including viruses (Novelli and 
Casanova, 2004).
IL-12 treatment in preclinical tumor models promotes immune surveillance 
against transplanted syngeneic tumors by inducing IFN-g-producing Th1 cells and the 
proliferation and cytotoxic activity of CD8+ T cells and natural killer cells. IL-12-induced
IFN-γ is not only rate limiting for T-cell activity but also induces the expression of major 
histocompatibility complex I and thereby allows increased recognition of tumor antigens 
(Wong et al., 1984). Tumor immune surveillance in mouse models is largely dependent
on IFN-γ-expressing T cells (Kaplan et al., 1998). Similar experiments using IL-23 
expressed in the transplanted tumor cell or systemically were equally efficient in rejecting 
syngeneic transplanted tumors (Lo et al., 2003).
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Interleukin-12 is therefore generally considered to promote antitumor effects, and 
cancer patients have been treated with recombinant IL-12 in several clinical studies
(Atkins et al., 1997). Dose-limiting toxicities were, however, observed before clinical 
benefits had been achieved. The toxicities appeared to be IFN-γ associated and were most 
likely the manifestations of a systemic immune response. Subsequent attempts combining
IL-12 therapy with a peptide vaccine have so far not revealed enhanced clinical benefits 
in the IL-12 treatment arms (Cebon et al., 2003). The difference in IL-12 and IL-23 
function against bacteria or tumors in mice and in man might be a reflection on the 
amount of infectious particles or the antigenic dose challenging the host defense. Most 
mouse models frequently use systemic exposure of the host to millions of colony-forming 
units of bacteria and viruses or injections with large numbers of tumor cells. Immune
recognition of human tumors might, however, follow a quite different kinetic, with only 
limited antigen exposure at first. The majority of infections in human patients are 
similarly not characterized by initial exposure to large numbers of infectious particles.
However, there are also striking differences in the regulation of immune surveillance to 
tumors in either IL-12- or IL-23-deficient animals. IL-12 deficiency increases not only 
the incidence of tumors but also allows for rapid tumor growth in mice. In contrast,
deficiency in IL-23 or the IL-23 receptor not only dramatically reduces tumor incidence 
but also reduces tumor growth of established tumors (Langowski et al., 2006). In the local 
tumor microenvironment, IL-23 not only induces the hallmarks of chronic inflammation
such as metalloproteases, angiogenesis and macrophage infiltration, but also reduces 
antitumor immunosurveillance by locally suppressing the presence of CD8-T cells.
In contrast, the absence of IL-12 leads to exacerbation of the myeloid-driven 
inflammation with a coincident lack of CD8 T cells (Langowski et al., 2006). 
Interestingly, it is IL-23p19 and IL12p40 that are found to be overexpressed in the 
majority of human cancers, not IL-12p35. In mouse models of autoimmune diseases, IL-
23 induces chronic inflammation in part through the stimulation of innate myeloid 
effector cells and stromal activation, and many aspects of IL-23-dependent tissue 
inflammation can be recapitulated in the absence of T cells (Uhlig et al., 2006). However, 
IL-23 also controls the activity of Th17 T cells. Although Th17 develop from naive T 
cells under the influence of TGF-b and IL-6, they subsequently require IL-23 to suppress 
endogenous IL-10 and become proficient in their pro-inflammatory function (McGeachy 
et al., 2007). This pro-inflammatory function orchestrates inflammatory tissue destruction 
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by the adaptive immune system. The induction of IL-17 by IL-23 in tumors is an 
attractive prospect because IL-17 promotes angiogenesis in a variety of models and
induces matrix metalloproteinases, two events that potentiate tumor growth (Numasaki et 
al., 2003).
In addition, IL-17 controls neutrophil chemotaxis, proliferation and maturation 
further fueling the innate immune activation (Kolls and Linden, 2004). IL-17 producing 
CD8 and CD4 T cells have recently been reported to be widely present in human and 
mouse tumor microenvironments (Kryczek et al., 2007). It has also been suggested that 
CD8 T cells expressing IL-17 largely lack cytotoxic capacity (Liu et al., 2007). It is 
important to note that IL-23 can induce, independent of IL-17, angiogenic erythema, 
inflammation and keratinocyte hyperproliferation, phenocopying aspects of human 
psoriatic lesions (Chan et al., 2006). Psoriatic disease does not correlate with increased 
incidence of malignancy (Rohekar et al., 2008). The IL-23-mediated physiological 
changes in the skin, however, strikingly resemble the microenvironment observed in early 
malignant lesions.
1.7.6 IL-1
Interleukin-1 is a pleiotropic cytokine that affects mainly inflammation and also 
contributes to immune and hemopoietic responses (Apte and Voronov, 2002; Dinarello, 
1996). The properties of IL-1 stem from its ability to induce the synthesis of cytokines, 
chemokines, proinflammatory molecules, and the expression of adhesion molecules. The 
IL-1 gene family consists of two major agonistic molecules, namely IL-1α and IL-1β, and 
one antagonistic cytokine, the IL-1R antagonist (IL-1Ra). IL-1α, IL-1β, and IL-1Ra are 
encoded by different genes. Both IL-1α and IL-1β differ from most other cytokines by 
lacking a signal sequence, thus not trafficking through the endoplasmic reticulum (ER)-
Golgi pathway; the precise mechanisms of IL-1 secretion are thus largely unknown (Apte 
and Voronov, 2002). IL-1α and IL-1β bind to the same receptors, and there are no
significant differences in the spectrum of activities of recombinant IL-1α or IL-1β when 
studied in vitro or in vivo in diverse experimental systems. However, endogenously 
produced IL-1α and IL-1β differ dramatically in the subcellular compartments in which
they are active. IL-1α is active in its secreted form (17.5 kDa), whereas the IL-1α 
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Figure 1.6: Representation of two outcomes of interactions between tumor cells and 
infiltrating inflammatory and/or immune cells in the tumor microenvironment.
Cytokines secreted by tumor and inflammatory/immune cells can either promote tumor development and
tumor cell survival or exert antitumor effects. Chronic inflammation develops through the action of various 
inflammatory mediators, including TNF-α, IL-6, and IL-17, leading to eradication of antitumor immunity 
and accelerated tumor progression. However, TRAIL, through direct induction of tumor cell apoptosis, IL-
10, through antiinflammatory effects, and IL-12, through activation of CTLs and NK cells and expression 
of cytotoxic mediators, can lead to tumor suppression. The multipleactions of TGF-β (cytotoxic in colon 
cancer cells, and having both positive and negative effects on the tumor microenvironment) and IL-23 
explain their dual roles in tumor development. (Lin and Karin, 2007).
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precursor is inactive; IL-1β is mainly active as an intracellular precursor (31 kDa) or as a 
membrane-associated form (23 kDa), but is only marginally active as a secreted 17.5 kDa
molecule. Mononuclear cells manifest the strongest secretory capacity of IL-1α and IL-
1β, whereas diverse nonphagocytic cells generally secrete low levels of IL-1β. IL-1α is 
only rarely secreted by living cells, except for activated macrophages, and in contrast to 
IL-1β, IL-1α is not commonly detected in blood or in body fluids, except during severe 
disease, in which case the cytokine may be released from dying cells. Diverse effects of 
the IL-1 molecules on tumor development have been described (Apte and Voronov, 
2002). On the one hand, antitumor effects of IL-1 have been described in experimental 
tumor systems, mainly due to its ability to costimulate T cell activation, to induce 
cytokine secretion in specific as well as nonadaptive immune cells, and to potentiate the 
differentiation and function of immune surveillance cells. On the other hand, IL-1 
potentiates invasiveness and metastasis of malignant cells, mainly by inducing adhesion 
molecule expression on the tumor cells as well as on endothelial cells (Apte and Voronov, 
2002; Dinarello, 1996). In addition, IL-1 may stimulate the production of invasiveness-
promoting factors such as matrix metalloproteinases, growth factors, or angiogenic 
factors by the malignant cells or by cellular elements in the tumor’s microenvironment. 
The diverse effects of the IL-1 molecules on malignant processes have hindered the use of 
IL-1 as an antitumor agent in clinical trials (Apte and Voronov, 2002).
1.8 Toll like Receptors (TLRs)
TLRs are best-known for their ability to recognize conserved microbial structures
that were originally named PAMPs (pathogen-associated molecular patterns) by Janeway
(1989). Despite their name, PAMPs are common to all microorganisms regardless of their 
pathogenicity. The best-characterized TLR microbial ligands are as follows: 
lipopolysaccharide (LPS; endotoxin) from Gram-negative bacteria, which stimulates 
TLR4; bacterial lipoproteins and lipotechoic acid and fungal zymosan, which stimulate 
TLR1, TLR2 and TLR6; bacterial flagellin, which activates TLR5; a profilin-like 
molecule from the protozoan Toxoplasma gondii, which activates TLR11; unmethylated
CpG motifs present in DNA that function as stimulators of TLR9; double-stranded RNA 
that activates TLR3; and single stranded RNA that can stimulate TLR7 and TLR8. In 
addition to microbial ligands, an increasing number of endogenous ligands are being 
reported as candidate stimulators of TLRs, in particular of TLR2 and TLR4. These 
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include heat shock proteins (HSP60, HSP70, endoplasmin, HSPB8 and α-crystallin A 
chain) (Vabulas et al., 2001; 2002), high mobility group box 1 (HMGB1) (Park et al., 
2002; 2004), uric acid crystals (Liu-Bryan, 2005), surfactant protein A (Guillot et al., 
2002), and various products of the extracellular matrix such as fibronectin (Okamura et 
al., 2001), heparan sulphate (Johnson et al., 2002), biglycan (Schaefer et al., 2005), 
fibrinogen (Smiley et al., 2001), oligosaccharides of hyaluronan (Termeer et al., 2002)
and hyaluronan breakdown fragments (Jiang et al., 2005; Taylor et al., 2007).
Data has indicated that TLRs (and IL-1–IL-18R signalling) have a crucial role in 
the development of tumours as they arise in their natural microenvironment, thus 
revealing a previously unknown aspect of tumorigenesis. It has been suggested that the 
response of stromal cells such as tissue-resident macrophages to the death of hepatocytes 
is crucial to the proliferation and expansion of pre-cancerous cells and tumour promotion
(Maeda et al., 2005). This promotion is the result of the NF-κB-dependent production of 
inflammatory mediators such as IL-6 following recognition of necrotic hepatocytes by 
tumour stroma (Maeda et al., 2005; Naugler et al., 2007). These studies indicate that TLR 
signalling contributes to the growth of tumours in numerous organs and thus may 
represent a general principle of tumorigenesis. Whether TLRs are involved in tumour
initiation is not yet clear. A formal role of TLRs in initiation with concatenate 
inflammation is yet to be determined; however, one can envision several possible roles 
for TLRs in initiation. TLR signalling has been shown to augment tumour cell adhesion
and invasion and increase vascular permeability (Wang, 2003), although a role for TLRs 
in the natural events of metastasis has yet to be determined, nonetheless, harnessing TLRs 
for cancer immunotherapy and vaccines is promising.
1.9 Lung cancer 
Lung cancer is a major health problem worldwide. The incidence is increasing 
globally at a rate of 0.5% per year. It is the leading cause of cancer mortality in most of 
the countries in the world (Jemal et al., 2002; Magarth and Litak, 1993). It remains the 
most lethal form of cancer in men and has now surpassed breast cancer in women as well 
in USA, where 170,000 new cases are diagnosed per year (Jemal et al., 2002). The 
worldwide incidence is 14% whereas it constitutes 6.8% of all cancers in India (Nanda 
Kumar, 2001). It is the leading cancer of both sexes in three of the Urban Cancer 
Registries (Bhopal, Delhi and Mumbai) in India (Nanda Kumar, 2001). In Kashmir it 
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ranks second among all cases in males. Non-small cell lung cancer accounts for nearly 
85% and small cell lung cancer accounts for 15% to 20% of cases. Despite advances in 
imaging techniques and treatment modalities, the prognosis of lung cancer remains poor, 
with a five-year survival of 14% in early stages and less than 5% in locally advanced
stages (Mghfoor and Michael, 2005; Montain, 1986). Unfortunately only 20-30% of 
patients present with an operable disease, while most of the patients present in an 
advanced stage II and III (Overholt et al., 1975). Evidently there is urgent need to 
understand the mechanistic details of lung cancer pathogenesis and devise strategies for 
its effective prevention. Evaluating immune interplay in lung tumorigenesis is an 
untreaded research area and as such holds great promise in unravelling therapies for lung 
cancer in particular and other carcinoma in general.
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Tumor escape from the host is facilitated by the ability of human tumors to 
actively subvert antitumor immunity by downregulating or completely suppressing local 
and systemic innate as well as adaptive antitumor immunity by a variety of mechanisms.
Several lines of evidence indicate that inflammatory cells and cytokines found in tumors 
are more likely to contribute to cancer progression rather than to mount an effective host 
anti-tumor response. Tumor-Infiltrating Macrophages (TIMs) are known to constitute a 
large part of tumors especially carcinomas (tumors of epithelial origin) and it is 
established that these TIMs are recruited from the circulating monocyte pool. The 
macrophages once in the tumor vicinity are ‘re-educated’ for a phenotype that is 
beneficial for tumor growth/progression/metastasis, which forms  a part of a broader 
concept of Immunoediting. The tumor favoring phenotype is brought about by the 
crosstalk through the microenvironment of the tumor cells and is mainly determined by 
the cytokine/chemokine milieu i.e. combination of pro-inflammatory and anti-
inflammatory cytokines. Some cytokines like TNF, IL-6, IL-10, IL-12, IL-1, IL-8, TGF-β 
are predominantly seen to be involved in generated such a milieu. The regulation of these 
cytokines skews the macrophage phenotype from Classical ‘M1’ to somewhat suppressed 
‘M2’, also called TAM (Tumor-Associated Macrophage) phenotype. Another important 
consequence of such cytokine milieu is suppression/regulation anti-tumor responses from 
Cytotoxic (NK & T) cells. This suppression is evaluated by studying the expression of 
cytokines specific to these cells like IL-2, IFN-γ, IL-10. Thus, TAMs are believed to be 
key orchestrators of cancer- related inflammation, and the neoplastic cells are thought to 
actively guide monocyte recruitment from blood into tumor tissues to their own 
advantage.
It becomes imperative and interesting to understand inflammatory mechanisms 
influencing the tumor microenvironment, in turn enabling to deduce the differences 
between inflammation that drives cancer progression and inflammation that inhibits 
tumor growth. Evaluation of the interaction between tumor cells with the immune cells 
especially the precursor cells like that of myeloid origin would certainly shed fresh 
insights on tumor development and immune evasion. Here, we try to evaluate the 
cytokine expression when immune cells are present in the immediate vicinity of the 
carcinoma cells especially lung carcinoma cells of human origin.
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2.1 Materials:
2.1.1 Chemicals and Reagents
3, 3’-diaminobenzidine tetrahydrochloride (DAB), 3, 3’, 5, 5’-Tetramethyl 
benzidine (TMB), phorbol 12-myristate 13-acetate (PMA), propidium iodide (PI), bovine 
serum albumin (BSA), and proteinase K were procured from Sigma Chemicals Co. (St. 
Louis, MO). Ficoll-Paque PlusTM reagents were purchased from Amersham Biosciences 
(Amersham, Piscataway, NJ). Src-kinase inhibitor Genistein, MAPK (MEK-1) inhibitor 
PD98059, p38 inhibitor SB202190, PI3 kinase inhibitor Ly294002, JNK inhibitor JNKII, 
NF-κB inhibitors PDTC, Whortmanin were obtained from Calbiochem (Darmstadt, 
Germany) and/or Cell Signaling Technology Inc. (Dancers, MA). EGFR (tyrosine kinase) 
inhibitor Tyrphostin AG1478, and Farnesyl Thiosalicylic acid (FTS) was procured from 
Caymen Chemicals Inc (USA). RPMI-1640, DMEM and fetal calf serum (FCS) were 
obtained from Biological Industries (Kibbutz, Israel). BMEM was obtained from Lonza 
Inc. (USA). Mouse TNF, Mouse IL-6, Human TNF-α, Human IL-6, Human IL-10, 
Human IL-12p40, Human IL-12p70, Human IL-1β detection kits were obtained from BD 
Biosciences (San Jose, CA) and eBiosciences Ltd. (San Diego, CA);. Micro BCATM
(bicinchoninic acid) protein assay kit was procured from Pierce (Rockford, IL). 
Nitrocellulose membranes for immuno-blotting were obtained from Advanced 
Microdevices Pvt. Ltd. (Ambala, India). Collagen and Fibronectin were procured from 
Sigma Chemical Co. (USA). The reagents used in electrophoresis and immuno-blotting 
were purchased from Sigma Chemical Co. (St. Louis, MO). Chemicals used in the 
preparation of buffers and other solutions were of analytical grade, and unless otherwise 
stated were obtained from E. Merck Ltd. (Mumbai, India). 
2.1.2 Cell lines
The human leukemic T cell line Jurkat, human monocytic cell line THP-1 were all 
obtained from American Type Culture Collection (ATCC) (Manassas, VA). The Human 
Adenocarcinoma Cell Line, A549, was a kind gift from Dr. Devinder Sehgal, National 
Institute of Immunology, New Delhi, India. Human undifferentiated cell line, ChaGoK-1, 
Human Colon Adenocarcinoma cell line, Caco-2, Human cervical cancer cell line, HeLa, 
Human T-cell line, Jurkat and Mouse macrophage cell line, RAW264.7,  were kindly 
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provided by Dr. Ayub Qadri, National Institute of Immunology, New Delhi. Mouse Lung 
carcinoma cell line, LL/2 (Lewis Lung carcinoma) was a kind gift from Dr. Rahul Pal, 
National Institute of Immunology. Human lung SV-40 transformed cell line, BEAS-2B 
was kindly provided by Dr. Balaram Ghosh Laboratory, Institute of Genomics and 
Integrative Biology, New Delhi, India.
2.1.3 Antibodies
TLR-2 antibody Monoclonal Anti-Human/Mouse CD282 TLR-2 purified Ab 
(T2.5 clone) was obtained from eBioscience (San Diego, CA). Human anti-CD3 antibody 
OKT3 were purified from culture supernatants (Hybridoma Laboratory, NII, New Delhi). 
Human anti-CD28 antibodies were obtained from eBiosciences Ltd. (San Diego, CA).
2.2 Preparation of buffers and other reagents
2.2.1 Phosphate-buffered saline (50mM phosphate, 150mM NaCl, pH 7.4)
Na2HPO4 40.5mM
NaH2PO4.2H2O 9.49mM
NaCl 150mM
2.2.2 PBS-Tween: Tween-20 was added to PBS to a final concentration of 0.05%.
2.2.3 Tris-buffered saline (Tris base, NaCl, pH 7.6)
For 10X
C4H11NO3  (Trizma Base)     24.2 g
NaCl                                       80 g
Adjust pH to 7.6 with conc. HCl.
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2.2.4 TBS-Tween: Tween 20 was added to TBS to a final concentration of 0.05%.
2.2.5 Protein Extraction buffer (SDS lysis buffer, pH 7.5)
Tris base                       20mM
EDTA                          1mM
SDS                               2%
2.2.6 Acetic acid-NaCl solution, pH 3.0
Acetic acid 0.1M
NaCl 0.15M
2.2.7 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)  
The solutions were prepared according to the following recipe:
2.2.7.1 Resolving gel (for 10ml)   12.0%
Acrylamide 30%, bis-acrylamide 0.8% 4.0ml (3.35ml for 10%)
Tris HCl buffer (1.5M Trizma base), pH 8.9 2.5ml 
H2O 3.35ml (4.0 ml for 10%)
SDS 10% 100µl
APS 10% 50µl
TEMED 8µl
      2.2.7.2 Stacking gel (for 5 ml)
Acrylamide 30%, bis-acrylamide 0.8% 0.65ml
Tris-HCl buffer (1M Trizma base), pH 6.8 0.65ml                  
H2O 3.65ml
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SDS 10% 50µl                                 
APS 10% 25µl
TEMED 6µl
SDS-Sodium dodecyl sulphate; APS-Ammonium persulphate; TEMED-N,N,N’N’-
Tetramethylethylenediamine.
2.2.7.3 Laemmli sample buffer (non-reducing)
Tris-HCl buffer, pH 6.8          0.16M
SDS                                         2.3%
Glycerol                                   10%
Bromophenol blue                  0.1% 
2.2.7.4 Electrode buffer
Glycine                                   192mM
Trizma base                             25mM
SDS                                         3.5mM
2.2.7.5 Staining solution
Coomassie brilliant blue      0.25%
Methanol                                40%
Glacial acetic acid                 10%
2.2.7.6 Destaining solution
Methanol                                  40%
Glacial acetic acid                    10%
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2.2.8 Western Blot
The reagents used in Western blotting were as follows:
2.2.8.1 Transfer buffer
Glycine                                   192mM
Trizma base                             25mM
Methanol                                  20%
2.2.8.2 Ponceau-S (10X)
Ponceau S                                26.3mM
Sulphosalicyclic acid                1.18M
Trichloroacetic acid                  1.84M      
2.2.8.3 Substrate for Western blot
0.05mg 3, 3’-diaminobenzidine was dissolved in 1ml PBS and 1l of 30% H2O2 was 
added. Substrate was prepared fresh.
2.2.9 Buffers for ELISA:
2.2.9.1 Carbonate buffer, pH 9.5
Na2CO3 32 mM
NaHCO3 74 mM
2.2.9.2 Citrate phosphate buffer, pH 5.6
Citric acid 22.1 mM
Na2HPO4 51.4 mM
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2.2.10 Substrates for ELISA
2.2.10.1 TMB-TBABH solution
3, 3’, 5, 5’-Tetramethyl benzidine (TMB) 41mM
Tetramethylammonium borohydride (TBABH) 8.2mM
N,N-Dimethylacetamide (DMA) 10ml 
The solution was stored in an airtight dark glass container at 4C. 
200l of TMB-TBABH solution and 3l of 30% hydrogen peroxide (H2O2) were added 
to 8ml citrate phosphate buffer. The substrate was prepared immediately before use.
2.2.10.2 Ortho-phenylene diamine (OPD)
0.5mg OPD was dissolved in 1ml citrate phosphate buffer and 1l H2O2 was 
added to it. The substrate was prepared fresh before use.
2.3 Methods
2.3.1 Maintenance of cell lines
Cells were maintained in RPMI-1640 (for THP-1, PBMC, Caco-2, ChaGoK-1, 
RAW264.7) or DMEM (for A549, HeLa, LL/2) or BEBM (along with additives i.e. 
fibronectin, collagen for BEAS-2B) supplemented with 10% heat inactivated fetal calf 
serum (RPMI-10) at 37C in a humidified CO2 (5%) incubator. Cells were centrifuged at 
315  g for 5 min, washed twice in serum-free RPMI-1640, resuspended in RPMI-10 and 
grown in 75cm2 tissue culture flasks. The cells were subcultured as per ATCC 
recommended guidelines.
2.3.2 Co-culture of Carcinoma (tumor) cells and immune cells
Representative Human Lung Carcinoma cells, A549 (Well differentiated 
Adenocarcinoma) & ChaGoK-1 (Undifferentiated Squamous Cell Carcinoma)  were co-
cultured with Human Monocytic cell line, THP-1 (in-vitro) and Peripheral Blood 
Mononuclear Cells, PBMCs (ex-vivo) in standardized ratio of ~1 : 10 for respective cell 
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types..  Similar, ratios were also used for co-cultures of Human Lung Epithelial cells, 
BEAS-2B (Transformed only), Human Colon Adenocarcinoma, Caco-2 and Human 
Cervical Adenocarcinoma, Hela, if not stated otherwise. Mouse co-culture systems 
between LL/2 and Raw264.7 or mixed co-cultures between Human tumor cells and 
Mouse macrophages or vice versa were also set accordingly. Tumor and Jurkat cells were 
used in ~1: 100 ratio.
2.3.3 Culture supernatants
Briefly, tumors cells were plated first and allowed to grow and adhere for about 
24 hours. Then, the culture media was taken out, the cells washed and added with 
monocytes along with fresh culture medium. Culture supernatants were collected at 
various time points and assayed for various cytokines. Also, conditioned media from 
tumor cells was collected at various time points, added to monocytes and culture 
supernatants were assayed for cytokines.
2.3.4 Protein estimation
Protein concentrations were determined using the Micro BCATM (bicinchoninic 
acid) protein assay kit (Pierce, USA). The assay was performed according to the 
instructions provided by the manufacturer. The dilutions of the sample were made in PBS 
and mixed with equal volume of reagent mix (B: C: A :: 24 : 1: 25). The plate was 
incubated at 37C for 1 h and absorbance was measured at 540 nm. BSA of known 
concentration provided with the kit was used as a standard.
2.3.4   SDS-PAGE
SDS-PAGE was carried out using the Laemmli buffer system (Laemmli, 1970). 
The resolving gel was polymerized in a Hoefer or BioRad Protean-3 mini gel apparatus 
for 30-45 min. The thickness of the gel was 1.5mm. The stacking gel prepared afresh was 
layered on top of the resolving gel and allowed to polymerize for 15-20 min. Samples to 
be analyzed were mixed with Laemmli sample buffer and placed in a heating block at 
100C for 5 min before loading into wells. Electrophoresis was carried out at a constant 
current of 30mA.
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2.3.5  Western Blot
Western blot was carried out by the method described by Towbin et al. (1979). 
The sample to be analyzed separated in a 12% SDS-PAG and transferred to a 
nitrocellulose (NC) membrane (MDI, India) at a constant current of 300mA for 2 h using 
a Bio-Rad transfer apparatus (BioRad, USA). The transfer of proteins was ascertained by 
staining the NC membrane with Ponceau-S (1X). The membrane was blocked for 1 h at 
room temperature with 1% non-fat milk protein prepared in PBS and subsequently probed 
with the appropriate primary antibody, followed by HRP-labeled secondary antibody and 
developed using Enhanced Chemiluminescence reagents. 
2.3.6 Human TNF-α, Human IL-6, Human IL-10, Human IL-12p40, Human IL-
12p70, Human IL-1β, Human IL-8, Human IFN-γ, Mouse TNF, Mouse IL-6 ELISA
The assay was carried out according to the instructions provided by the 
manufacturer with slight modifications. Briefly, a 96-well microplate (Maxisorp, Nunc) 
was coated overnight at 4C with 50µl capture antibody (diluted 1: 250 in 100mM 
carbonate buffer, pH 9.5 or as provided in manufacturers-BD Biosciences instructions). 
The plate was washed 3 times with PBS-Tween (PBST) and blocked with PBS-BSA-1% 
(200l/well) for 1 h at 37C. After washing, samples were added to each well and the 
plate was incubated for 1 h at 37°C. Subsequently, the plate was washed and incubated 
with detection reagent mix (detection antibody + avidin-HRP) diluted 1: 250 in PBS-BSA 
1%. After 1 h incubation, the plate was washed and the enzyme activity determined by 
adding freshly prepared substrate solution containing TMB/TBABH/H2O2 (75µl/well). 
The reaction was stopped with 125µl of 2N H2SO4 and the absorbance was read at 450nm
(or as advised in manufacturer’s instructions. 
2.3.7 Generation of Macrophage precursors and T cell blasts from human PBMCs
Blood was collected in heparin-coated vacutainers, by venipuncture from healthy 
human volunteers. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-
Paque density gradient centrifugation. Briefly, fresh heparinized blood was diluted with 
an equal volume of PBS and slowly layered over Ficoll-Paque solution in 15ml poly-
propylene tubes. 3ml of Ficoll-Hypaque was used per 10ml of blood/PBS mixture. The 
tubes were centrifuged at 2000 × g for 30 min at 20C. The upper layer containing the 
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plasma and most platelets was removed and the mononuclear cell layer at the 
plasma/Ficoll-Paque interface was collected in a separate tube (Strober W, 2001). For 
Macrophage precursors, these cells were plated (24 well or 6 well or 25-cm2 flask) for 12 
hours. The adhering cells were analysed as macrophage precursors. The non-adherent cell 
were further analysed for cell blast generation. For T-cell blast generation, these non-
adherent cells were washed with RPMI-1640, resuspended in RPMI-10 containing 
2g/ml of anti-CD28 antibody. Cells were then transferred to a 25-cm2 flask (or in plates)
coated with 10g/ml of anti-CD3 antibody, and incubated for 48 h at 37C. Dead cells 
were removed by Ficoll-Paque density gradient centrifugation and live cells were used to 
study effect of cell-free extracts . 
2.3.8 Wound Healing Assay
Wound Healing Assay is used to study the effects of a variety of experimental 
conditions on cell migration and proliferation. Briefly, cells were grown in DMEM/RPMI
supplemented with 10% FBS. Cells were seeded into 24-well or 6 well tissue culture 
plates in a density that, after 24 hours of growth, they should reach ~70-80% confluence 
as a monolayer. Gently and slowly a scratch (wound) was made on the monolayer with a 
new 1 ml pipette tip across the centre of the well. While scratching across the surface of 
the well, the long-axial of the tip was kept perpendicular to the bottom of the well. 
Scratch a straight line in one direction. After scratching, the wells were gently washed
twice with medium to remove the detached cells. The well/s was replenished with fresh 
medium. (Medium may contain ingredients of interest, e.g., components that 
inhibit/promote cell motility and/or proliferation.) Cells were grown for additional 48 
hours (or the time required). Cells were washed twice with 1x PBS, then fixed with 3.7% 
paraformaldehye for 30 minutes/ or directly visualised and photographed. Same 
configurations of the microscope were maintained while taking pictures for different 
views of the stained monolayer or monolayer of comparing wells. 
2.3.9 Propidium Iodide (PI) Staining
Propidium iodide (PI) is a membrane impermeant dye that is generally excluded 
from viable cells. It binds to double stranded DNA by intercalating between base pairs. PI 
is excited at 488 nm and, with a relatively large Stokes shift, emits at a maximum 
wavelength of 617 nm. Because of these spectral characteristics, PI can be used in 
Materials and Methods
48
combination with other fluorochromes excited at 488 nm such as fluorescein 
isothiocyanate (FITC) and phycoerythrin (PE). Cells were harvested and aliquoted up to 1 
x 106 cells/100 μL into FACS tubes. Cells washed 2 times by adding 2 mL of PBS, 
centrifuged at 300 x g for 5 minutes, and then decanted for buffer from the pelleted cells.
Cells were re-suspended in 100 μL of Flow Cytometry Staining Buffer. To adjust flow
cytometer settings for PI, 5 - 10 μL of PI staining solution was added to a control tube of 
otherwise unstained cells followed by gentle mixing and incubation for 1 minute in the 
dark. PI fluorescence (using the FL-2) was determined with a BD FACS caliber™
instrument. Data was acquired for unstained cells and single-color positive controls. 5 -
10 μL of PI staining solution was added to each sample just prior to analysis. The stop 
count was set on the viable cells from a dot-plot of forward scatter versus PI.
2.3.10 Inhibitor Assay
Tumor cells were treated with various signaling inhibitors for two (2) hours after 
overnight plating. Cells were washed 3-5 times with serum free culture medium to wash 
off the inhibitors. Subsequently, tumor cells were co cultured (as shown in section 2.3.2) 
and assayed for cytokines in the culture supernatants.
2.3.11 Concentration of Inhibitors 
The viable inhibitor concentrations were first standardized for each tumor cell 
type based on their IC50 scores. Subsequently, the concentrations used were
MAPK (MEK-1) inhibitor, PD98059 200µM
p38 inhibitor, SB202190 50µM
PI3 kinase inhibitor, Ly294002 10µM
JNK inhibitor, JNKII 50µM
NF-κB inhibitor, PDTC 200µM
Whortmanin 10nM
DMSO was the vehicle (solvent) for inhibitors.
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2.3.12 TLR-2 Blocking Assay
Tumor cells were incubated with TLR-2 blocking antibody (Monoclonal Anti-
Human/Mouse CD282 TLR-2 purified Ab) alongwith its Isotype (IgG1) control for two 
(2) hours at room temperature after overnight plating. Cells were washed 3-5 times with 
serum free culture medium to wash off any free antibody. Subsequently, tumor cells were 
co cultured (as shown in section 2.3.2) and immune-assayed for cytokines in the co-
culture supernatants.
2.3.13 Statistical Analysis
Statistical analysis was done using Graph Pad Prism (Ver. 5.0) software. For 
comparative studies, data were analyzed by One Way ANOVA with multiple 
comparisons using Dunnett’s test. Data were represented as Mean ± SD and values were 
considered statistical significant for p <0.05 (CI = 95%) from atleast three (or five)
independent experiments or otherwise mentioned.
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3.1 Tumor cells induce regulated expression of Tumor Necrosis Factor 
(TNF-α) from monocytes
3.11 A549 cells trigger Tumor Necrosis Factor-α from Monocytes
We used a co-culture system, which mimics the actual microenvironment 
scenario, to study the interaction between immune cells especially monocytes with tumor 
cells. TNF-α is a well known pro-inflammatory cytokine and secreted upfront in most 
immune responses. When Human Lung Adenocarcinoma cells, A549 were co-cultured 
with Human Monocytes, THP-1, TNF-α was detected in the culture supernatants from 
these co-cultures. Next, we co-cultured A549 cells with THP-1 cells at various cell 
numbers to standardise the cell ratios for optimal responses. A549 and THP-1 cells did 
not express TNF-α by themselves. Tumor cell numbers ranging from 103 to 2×105 were 
co-cultured with 2×105 THP-1 cells in 24 well cell culture plates. It is observed that the 
ratio of 1: 10 of tumor and monocytes cells, respectively, gave optimal TNF-α response
(Figure 3.1). Incidentally, tumor cells and myeloid cells in similar ratios are seen 
intervasating solid tumors or carcinoma. For the following co-culture experiments we 
maintained such ratios.
3.12 Tumor Necrosis Factor-α (TNF-α) expression is early and robust from in all co-
culture systems
To check whether the expression of TNF-α was specific to A549 cells or the 
expression could be corroborated with other co-culture systems with tumor cells of 
different origins we co-cultured representative tumor cells of colon, Caco-2 and cervix, 
HeLa with THP-1 cells at already mentioned ratios i.e. ~ 1:10. We immunoassayed for
TNF-α expression and deduced that all model tumor cells when co-cultured with THP-1 
cells gave robust TNF responses (Figure 3.2). Following the kinetics of TNF-α expression 
in the co-culture supernatants it is observed that TNF is detectable as early as 1 hour post 
co-culture. The response peaks around 4-6 hour time point and recedes thereafter. It is 
noteworthy that a potent TNF-α concentration of ~1000 pg/ml is achieved in all co-
cultures, indicating to a definitive role during the interaction of these two cell types. The 
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Figure 3.1: TNF expression in culture supernatants of A549 and THP-1 at denoted 
cell numbers. Data were represented as Mean Concentration of TNF-α ± SD. Values 
were considered as statistically significant for p < 0.05 from at least five independent 
experiments.
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Figure 3.2: TNF-α expression kinetics in co-cultures of various Carcinoma (5 x 104) 
+ THP-1 (2 x105) cells. (Data were represented as Mean Concentration of TNF-α ± SD.
Values were considered as statistically significant for p < 0.05 from atleast five 
independent experiments.
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receding levels of TNF-α also underline this argument. The tumor cell number affects the 
potency but not the kinetics of the response, probably owing to concentration of the 
stimulus from tumor cells. The response is faster and as robust, if not more, than the 
known ligands of TNF activation from THP-1 cells like Flagellin, LPS and Pam3CSK4 
(from previous experiments-data not shown).                   
3.13 Conditioned medium (C.M.) from tumor cells also initiates Tumor Necrosis Factor 
(TNF-α) expression in monocytes but with different kinetics 
To validate the response from human PBMCs in co-culture systems,  2×104 A549, 
Caco-2 and HeLa cells were co-cultured with  ~ 0.25 million PBMCs obtained by Ficoll-
Paque (GE Amersham) on blood from volunteers (Section 2.3.7). TNF-α expression is 
robust and correlates well with kinetics seen with THP-1 cell based co-cultures, presented 
previously. Again, the decrease of TNF at later time points emphasises the possible role
of TNF. This would mean that either the already released TNF is consumed rapidly at 
these late time points or the expression is regulated (or switched off) after achieving a 
threshold.
To ascertain the nature of the stimulus that triggered the TNF-α expression, 
conditioned medium from tumor cells (24 hour culture medium of ~ 80% confluent cells) 
was incubated with monocytes. Although, in all cell-cell co-culture systems, TNF levels 
peaked at around 6 hours after co-culture and receded thereafter but when PBMCs were 
treated with Conditioned Medium from tumor cells such kinetics was altered, as the 
receding of TNF levels at later time points was not observed (Figure 3.3). This also holds 
well when THP-1 cells are treated with Conditioned Medium as well (from previous 
experiments-data not shown). Thus, the stimulus was not only tumor cell associated but 
also secretory in nature. The absence of late recession of TNF-α levels in conditioned 
medium treated monocytes emphasises sensing of TNF-α by tumor cells and actually 
regulating its expression. The fact that such expression is seen in all the co-cultures under 
study underlines the importance of this cytokine based interaction. 
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Figure 3.3: TNF-α expression in co-cultures of various
(a) Carcinoma cells (5*104) + adh. PBMCs (2.7 x 105) cells, and
(b) their Conditioned Media + adh. PBMCs (2.7 x 105) cells.
(Data were represented as Mean Concentration of TNF-α ± SD. Values were considered 
as statistically significant for p < 0.05 from atleast five independent experiments).
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3.14 Comparative TNF response kinetics from Monocytes triggered by various cells of 
human lung origin
Cells of human lung origin A549, ChaGoK-1 and BEAS-2B were co-cultured 
with THP-1 at various cell numbers. The potency and universality of the effector TNF 
inducing ligand(s) was evaluated by screening for TNF-α responses from monocytes, 
which apparently is one of the first cytokines to be triggered. Comparison of the TNF 
expression kinetics reveals that though A549 cells are more potent than ChaGoK-1 and 
BEAS-2B cells, especially at lower cell numbers, all tumor cell types of the lung origin 
elicit TNF-α expression with typical kinetics (Figure 3.4). This further strengthens the 
argument that the phenomenon of cytokine induction may be common for carcinomas or 
solid tumors.
3.15 Murine Lung tumor cells initiate secretion of TNF from mouse macrophages
LL/2 or LLC (lewis lung carcinoma) cells, the representative murine tumor cells 
co-cultured with Mouse macrophages, RAW264.7 were studied for TNF release. TNF 
was detected in mouse co-culture supernatants as well (Figure 3.5). This suggests to 
similarities in TNF induction in mouse and human models.
3.16 Human Lung carcinoma cells are able to initiate TNF from Mouse Macrophages
Epithelial cells are not known to express TNF-α and as such the TNF-α expression 
in the co-cultures is attributed to monocytes.  To validate this, mouse macrophages i.e. 
RAW264.7 were co-cultured with lung tumor cells of human origin i.e. A549, at already 
established cell ratios. Indeed, only mouse TNF was detected in co-culture supernatants, 
confirming that the origin of TNF was strictly from macrophages or monocytes. Again, 
TNF was detected as early as 1 hour post co-culture, which is strikingly similar to human 
co-culture system (Figure 3.6). Thus, the potency of the TNF inducing stimulus is 
comparable between human and murine origins. These findings also point to similarity of 
the stimulus for TNF induction in human and mouse systems. In other words, the 
cytokine triggering factors(s) from tumor cells from human and mouse carcinoma cells 
may be common.
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Figure 3.4: Human TNF-α (hTNF) expression in co-cultures of THP-1 with 
A549/ChaGoK-1/BEAS-2B cells (Comparative kinetics) at 2 hour time point. Data 
were represented as Mean Concentration of TNF-α ± SD. Values were considered as 
statistically significant for p < 0.05 from atleast five independent experiments.
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Figure 3.5: LL/2 cells induce TNF expression from RAW264.7 cells. (LL/2: 2×104
cells; RAW264.7: 2×105 cells). Data were represented as Mean Concentration of TNF ± 
SD. Values were considered as statistically significant for p < 0.05 from atleast five 
independent experiments.
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Figure 3.6: Murine TNF expression in co-cultures of A549 and RAW264.7 cells at 
various cell-cell ratios. Data were represented as Mean Concentration of mTNF ± SD.
Values were considered as statistically significant for p < 0.05 from atleast five 
independent experiments.
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3.17 Methanol fixed A549 cells are able to induce TNF-α from Monocytes without 
regulation
To gain more insights into the nature of TNF inducing stimulus from tumor cells, 
we compared TNF-α expression of A549 and THP-1 co-culture with methanol fixed 
A549 and THP-1 co-culture. Methanol fixing renders the cells dead and as such the
generation and regulation of TNF inducing stimulus would also cease. Surprisingly, the
TNF-α inducing capability is hardly affected but there is loss of regulation as TNF-α 
levels do not recede in co-cultures of methanol fixed A549 cells (Figure 3.7). It can be 
inferred that viable tumor cells actually sense and regulate the TNF-α levels in the co-
culture. Since no fresh stimulus is synthesised by tumor cells after fixing, it is suspected 
that there is considerable amount of stimulus already available on the cells. The fact that 
the fixed A549 cells trigger much stronger TNF responses (Figure 3.7) indicates the 
possible release of already stocked up TNF inducing factor(s) upon fixing of tumor cells.
3.2 Co-culture of carcinoma cells and monocytes leads to strong 
Interleukin (IL)-6 release
3.21 Interleukin-6 expression is induced early in exorbitant amounts from THP-1 and 
adherent PBMCs (macrophages) by tumor cells
IL-6 from macrophages is considered as one of the major cytokines responsible in 
tumor establishment and progression. Immunoassays for IL-6 in co-culture supernatants 
of A549 and THP-1 indicated strong expression much like TNF-α. When various tumor 
cell numbers against monocytes were considered, again, the in vivo ratio of ~ 1:10 
showed optimal IL-6 response (Figure 3.8).
IL-6 is triggered early like TNF from PBMCs and is expressed in very high 
concentrations in co-cultures as well as Conditioned Media (from tumor cells) treated 
PBMCs (Figure 3.9). A549, Hela, Caco-2 and their Conditioned Media are able to induce 
IL-6 expression in co-cultures, again pointing to similar nature of the stimulus and similar 
mechanisms of induction for all carcinoma cell types. The kinetics of IL-6 expression is
comparable for all co-cultures as well as conditioned media treated PBMCs. Presence of 
IL-6 seems to be relevant even at later time points as no dip in expression levels is
observed, instead PBMC’s keep expressing more IL-6, unlike the TNF responses.
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Figure 3.7: TNF-α expression in culture sups of methanol-fixed A549 + THP-1 co-
cultures & A549 + THP-1 co-cultures (THP-1: 2x105). Data were represented as Mean 
Concentration of TNF-α ± SD. Values were considered as statistically significant for p < 
0.05 from atleast five independent experiments.
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Figure 3.8: IL-6 expression in culture supernatants of A549 and THP-1 co-cultures 
at varied cell numbers. Data were represented as Mean Concentration of IL-6 ± SD.
Values were considered as statistically significant for p < 0.05 from atleast five 
independent experiments.
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Figure 3.9: Human IL-6 expression in co-cultures of various
(a) Carcinoma cells (5*104) + adherent PBMCs (2.7*105) cells, and
(b) their Conditioned Media (C. M.) + adherent PBMCs (2.7*105) cells.
(Data were represented as Mean Concentration of TNF-α ± SD. Values were considered 
as statistically significant for p < 0.05 from atleast five independent experiments).
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Figure 3.10: Detection of human IL-6 in culture supernatants of A549 and 
RAW264.7 co-cultures. Data were represented as Mean Concentration of IL-6 ± SD.
Values were considered as statistically significant for p < 0.05 from atleast five 
independent experiments.
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3.22 Human IL-6 detected in co-cultures is partially secreted by tumor cells
IL-6 apart from being secreted by almost all cells of the immune system in 
response to an insult, is also known to be expressed in an autocrine manner by epithelial 
cells. To verify this, A549 cells were co-cultured with RAW264.7 cells at various cell 
ratios. Significantly, human IL-6 was detected in the co-culture supernatants (Figure 
3.10). This indicates that tumor cells contribute partially to the IL-6 expression in the co-
culture while the rest comes from monocytes. It can also be inferred that the autocrine IL-
6 is induced only after coming in contact with monocytes pointing to IL-6 inducing signal 
coming from monocytes. Also, the autocrine IL-6 expression, especially at late time 
points (Figure 3.10), could be responsible for differences in late kinetics when compared 
with TNF-α expression in the co-cultures.
3.3 Factor(s) from carcinoma cells also trigger IL-10, IL-12p40 from 
monocytes but no IL-1β or IL-12p70
3.31 Interleukin-10 is vehemently triggered from monocytes upon continued co-culture
by A549 cells and A549-Conditioned Medium compared to other tumor cell types 
The tumor associated alternative-M2 like phenotype of macrophages or their 
precursors is characterised by high IL-10 and low IL-12 expression in the 
microenvironment. The culture supernatants from co-cultures of A549, ChaGoK-1 and 
Caco-2 cells with adherent PBMCs (macrophages) and macrophages treated with 
Conditioned Medium from tumor cells were assayed for IL-10, an anti-inflammatory 
cytokine. A549 cells and its Conditioned medium were observed to be equally potent to 
induce high levels of IL-10 from macrophages (Figure 3.11). In comparison, ChaGoK1, 
Caco-2 and their respective Conditioned medium were feeble but significant inducer of 
such response (Figure 3.11). IL-10 was not detectable at earlier time points (not shown), 
suggesting that IL-10 is exerting its influence after the initial spike of TNF induction from 
PBMCs. This could also suggest that the cytokine milieu shifts from pro-inflammatory to 
anti-inflammatory phenotype. Also, the initial pro-inflammatory response could serve as a 
necessary trigger for the following response.
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Figure 3.11: Human IL-10 in co-cultures of various 
(a) Carcinoma cells (5x104) + adherent PBMCs (2.7x105) cells, and
(b) their Conditioned Media (C.M.) + adherent PBMCs (2.7x105) cells at 30 hour 
post coculture.
(Data were represented as Mean Concentration of IL-10 ± SD. Values were 
considered as statistically significant for p < 0.05 from atleast five independent 
experiments).
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Figure 3.12: Mouse IL-10 in culture supernatants from A549+RAW264.7 co-
cultures. Data were represented as Mean Concentration of IL-10 ± SD. Values were 
considered as statistically significant for p < 0.05 from atleast three independent 
experiments.
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Figure 3.13: IL-12p40 expression in co-culture of A549 with adherent PBMCs. Data 
were represented as Mean Concentration of IL-12p40 ± SD. Values were considered as 
statistically significant for p < 0.05 from atleast five independent experiments.
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Again to confirm the origin of IL-10 in co-culture supernatants, A549 cells were 
co-cultured with RAW264.7 and analysed for IL-10. Indeed, mouse IL-10 was detected in 
these supernatants (Figure 3.12). By now, it seems certain that the cytokine inducing 
stimulus is conserved for human and mouse cell types.
3.32 IL-12p40 but not IL-12p70 is significantly expressed in Cell/Cell co-cultures 
A critical cytokine for NK and T cell activation, IL-12 has two sub units p70 and 
p40. The p40 sub-unit is shared with another cytokine IL-23. Co-culture supernatants of 
A549, ChaGoK-1, Caco-2 cells and their Conditioned Media co-cultured with adherent 
PBMCs were assayed for p40 sub-unit of IL-12. Tumor cells only and not their 
conditioned media induced significant IL12p40 from adherent PBMCs, shown in Figure 
11. Of the tumor cells assayed, A549 induction of IL-12p40 was most potent. Like IL-10, 
IL-12p40 is not detectable at early time points but is expressed almost simultaneously 
with IL-10. This is interesting because it indicates similar mechanisms of control in cell-
cell co-cultures.
3.33 IL-1β and IL-12p70 were not detectable in these co-cultures
We also assayed for IL-1β, an important pro-inflammatory cytokine and p70 sub-unit of 
IL-12 in co-culture supernatants but could not detect any expression at any of the time points that 
we have looked at. This suggests that IL-12p40 detection could well be indicative of IL-23 
expression, a known anti-inflammatory cytokine.
3.4 Toll-like receptor (TLR)-2 engagement on monocytes triggers cytokine 
responses
3.41 Tumor necrosis factor (TNF)-α expression is completely abrogated by blocking 
TLR-2 on Monocytes
TNF-α and other major cytokine secretion from cells of immune system is 
attributed to the activation of MyD88 signalling pathway. As such, the release of all the 
cytokines described thus far could involve TLR mediation. To unravel the receptor on 
monocytes, with the presumption of TLR involvement, to which the stimulus/ligand for 
TNF-α induction binds, THP-1 cells were blocked with 10µg/ml of anti-TLR-2 antibody 
(eBiosciences) for 30 minutes before co-culture. TLR-2 blocking on THP-1 cells
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Figure 3.14: TNF-α in co-cultures of TLR-2 blocked THP-1 (5 x 104) +A549 (104) 
cells/conditioned medium (C. M.) of A549 cells. Data were represented as Mean 
Concentration of TNF-α ± SD. Values were considered as statistically significant for p < 
0.05 from atleast five independent experiments.
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Figure 3.15: TNF-α in co-cultures of TLR-2 blocked adh. PBMCs (2.7*105) +A549 
(5*104) cells. Data were represented as Mean Concentration of TNF-α ± SD. Values 
were considered as statistically significant for p < 0.05 from atleast five independent 
experiments.
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Figure 3.16: TNF-α in co-cultures of TLR-2 blocked THP-1 (2 x 104) + 
A549/ChaGoK-1/Caco-2 (12x 104) cells. Data were represented as Mean Concentration 
of TNF-α ± SD. Values were considered as statistically significant for p < 0.05 from 
atleast five independent experiments.
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completely abrogated TNF responses triggered by A549 cells as well as Conditioned 
Medium of A549 cells (Figure 3.14). Monocytes were blocked for TLR-4 (data not 
shown) but it had no effect on TNF-α expression (see section 2.3.12).
Similar to THP-1 cells, TNF-α expression induced by tumor cells was 
compromised from PBMCs when blocked with 2µg/ml of anti-TLR-2 antibody for 30 
minutes before co-culturing with A549 cells (Figure 3.15). Thus, it is clear that the 
stimulus from tumor cell engages TLR-2 to activate TNF-α expression from monocytes.
The abrogation of TNF responses was also achieved in ChaGoK-1 and Caco-2 co-
cultures, by blocking of THP-1 cells with 2µg/ml of anti-TLR-2 antibody (Figure 3.16)
implying that all tumor cells expressed TLR-2 agonist(s) to initiate TNF-α expression.
3.42 IL-6 expression is partially obviated by blocking TLR-2 on adherent monocytes 
(macrophages):
To identify the binding partner of the IL-6 inducing stimulus/ligand(s) on PBMCs 
in the co-cultures, adherent PBMCs were first blocked with 2µg/ml of anti-TLR-2 
antibody for 30 minutes before co-culturing with A549 cells. The response, shown in 
Figure 3.17, was obviated, though partially.  It is evident that TLR-2 binding of the 
ligand(s) leads to IL-6 response from monocytes/macrophages. Thus, it seems that 
ligand(s) for IL-6 and TNF induction act through engaging of TLR-2. The partial 
blockade by anti-TLR-2 could be attributed to autocrine expression of IL-6 by tumor 
cells.
3.43 IL-10 induction is subverted by TLR-2 blocking of monocytes
Considering that TNF and IL-6 were induced by engaging TLR-2 on Monocytes 
(macrophages), we checked whether TLR-2 was the receptor for IL-10 triggering 
stimulus too. Again, PBMCs were blocked with 2µg/ml of anti-TLR-2 antibody for 30 
minutes before co-culturing with A549 cells. Indeed, IL-10 expression was subverted by 
TLR-2 blockade (Figure 3.18), indicating that such a response is TLR-2 mediated. 
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Figure 3.17: IL-6 expression in co-cultures of TLR-2 blocked adh. PBMCs (2.7x105) 
+A549 (5x104) cells. Data were represented as Mean Concentration of IL-6 ± SD.
Values were considered as statistically significant for p < 0.05 from atleast five 
independent experiments.
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Figure 3.18: IL-10 expression in co-cultures of TLR-2 blocked adh. PBMCs 
(2.7x105) +A549 (5x104) cells. Data were represented as Mean Concentration of IL-10 ± 
SD. Values were considered as statistically significant for p < 0.05 from atleast five 
independent experiments.
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Figure 3.19: IL-8 expression in co-cultures of TLR-2 blocked A549 (104) cells/serum 
free medium of A549. Data were represented as Mean Concentration of IL-8 ± SD.
Values were considered as statistically significant for p < 0.05 from atleast five 
independent experiments.
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3.44 Constitutive IL-8 expression by A549 is not affected by TLR-2 blocking
A549 cells express IL-8, a pro-inflammatory and pro-angiogenic cytokine, 
constitutively (from previous experiments). IL-8 is known to attract neutrophils and NK 
cells. To evaluate the possibility of TLR-2 agonist based activation of A549 cells to bring 
about IL-8 expression and thus forming an active autocrine loop, A549 cells were blocked 
with 2µg/ml of anti-TLR-2 antibody for 30 minutes and then assayed for IL-8 at various
time points (Figure 3.19). However, TLR-2 blocking did not affect the constitutive 
expression of IL-8 from A549 cells.
3.5 TLR-2 agonistic activity of tumor cells is regulated by MAP Kinase 
pathway but is independent of EGFR and Ras signaling
3.51 EGFR and Ras independent pathway regulates the TLR-2 agonistic activity of 
tumor cells
Mutations that lead to EGFR (tyrosine kinase) overexpression (known as 
upregulation) or overactivity have been associated with a number of cancers, including 
lung cancer. Mutations, amplifications or misregulations of EGFR or family members are 
implicated in about 30% of all epithelial cancers. On the other hand, Ras proteins function 
as binary molecular switches that control intracellular signaling networks. Ras-regulated 
signal pathways control such processes as actin cytoskeletal integrity, proliferation, 
differentiation, cell adhesion, apoptosis, and cell migration. Of the major intracellular 
pathways involved in tumorigenesis is Ras mediated pathway. Ras is the most common 
oncogene in human cancer - mutations that permanently activate Ras are found in 20-25% 
of all human tumors. Mutations or hyperactivity of EGFR and Ras tend to be mutually 
exclusive. As such these both were suspected to be involved in control of TLR-2 
agonist(s) from tumor cells.
Pre-treating the representative tumor cells with EGFR (tyrosine kinase) inhibitor, 
AG1478 and Ras inhibitor, FTS , followed by co-culture with monocytes the expression
of TNF-α was studied.  No significant change in TNF-α expression was observed (Figure 
3.20). Pharmacological inhibition of both EGFR and Ras did not affect the TNF-α 
inducing TLR-2 agonist(s) activity of tumor cells. This indicates involvement of some 
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other signaling pathway in regulation of factor(s) from tumor cells that induce cancer 
related inflammatory responses.
3.52 Intracellular MAP Kinase pathway regulates TLR-2 agonistic activity of 
carcinoma cell
Major intracullar signalling pathways include Mitogen activated protein (MAP) 
Kinase pathway, Phosphotidylinositide (PI)-3 kinase pathway, Nuclear factor (NF)-κB 
pathway. To deduce the intracellualar pathway that supervise the tumor factor(s) leading 
to inflammatory responses , tumor cells were treated with various inhibitors seperately 
before co-culturing them with monocytes (see section 2.3.10). The non-toxic 
concentrations were standardised for each cell type before setting up co-cultures (see 
section 2.3.11). Expression of TNF-α was taken as indicator of induction of cancer related 
inflammtory reponse.
Inhibition of MEK-1 (MAP kinase) , by MEK-1 specific inhibitor PD98059, in 
lung origin tumor cells  (A549 and ChaGoK-1) showed abrogation of TNF-α from co-
culture supernatants (Figure 3.21). Pharmacological inhibition by SB202190, p38 
inhibitor, also lead to partial subversion of inflammatory responses.
Interestingly, when HeLa and Caco-2 cells were pretreated with inhibitors 
followed by co-culture with monocytes, maximal inhibition was observed in co-cultures 
with PD98059 treated tumor cells (Figure 3.22). This substantiates that MEK-1 and in 
turn MAP Kinase is involved in relation of TLR-2 agonistic activity of carcinoma cells. 
Partial involvement of p38 signaling also corroborates MAP Kinase involvement in 
control of inflammation inducing tumor factor(s).
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Figure 3.20: Effect of EGFR and Ras inhibition on TLR-2 ligand regulation in 
tumor cells. (AG1478 (tyrphostin) – EGFR inhibitor; FTS – Ras inhibitor). Data were 
represented as Mean Concentration of TNF-α ± SD. Values were considered as 
statistically significant for p < 0.05 from atleast five independent experiments.
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Figure 3.21: Effect of various intracellular signaling inhibitors on TLR-2 agonistic 
activity of (a) A549 and (b) ChaGoK-1 cells. Data were represented as Mean 
Concentration of TNF-α ± SD. Values were considered as statistically significant for p < 
0.05 from atleast five independent experiments.
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Figure 3.22: Effect of various intracellular signaling inhibitors on TLR-2 agonistic 
activity of (a) HeLa and (b) Caco-2 cells. Data were represented as Mean 
Concentration of hTNF ± SD. Values were considered as statistically significant for p < 
0.05 from atleast five independent experiments.
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3.6 Synergy of tumor cells and monocytes enhances proliferation of tumor 
cells and viability of monocytes
3.61 Co-culture of Lung carcinoma cells with monocytes enhances monocyte viability
Such keenly regulated inflammatory microenvironment is bound to affect the 
properties of all cells involved. After all the consideration is that tumor cells are 
manipulating other cells especially precursor myeloid lineage to evade immune 
responses. To analyze the effect of this typical inflammatory environment and continuous 
crosstalk with tumor cells, on monocytes, A549 cells were co-cultured with THP-1 cells 
for 96 hours. Under normal circumstances such prolonged cultures began to show 
substantial dead or dying cells. 
The suspended THP-1 cells in the co-culture were separated and stained for 
Propidium Iodide against relevant controls (see section 2.3.9). The normal culture of 
THP-1 cells grown for 96 hours showed 28.2 % dead or dying cells as depicted in Figure 
3.23 (b). Strikingly, the THP-1 cells from 96 hour co-cultures showed only 2.7 % dead or 
dying cells as depicted in Figure 3.23(a). Fresh THP-1 culture of 24 hours showed only 
0.9 % unhealthy cells represented in figure 3.23(c). This indicates that continuous 
interaction of monocytes with tumor cells leads to better viability of monocytes. 
3.62 TNF rich co-culture supernatant induces proliferation, invasiveness of tumor cells
The wound-healing assay is simple, inexpensive, and one of the earliest developed 
methods to study directional cell migration in vitro. This method mimics cell migration 
during wound healing in vivo. The basic steps involve creating a "wound" in a cell 
monolayer, capturing the images at the beginning and at regular intervals during cell 
migration to close the wound, and comparing the images to quantify the migration rate of 
the cells. It is particularly suitable for studies on the effects of cell-cell interactions on cell 
migration.
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Figure 3.24: Wound healing in A549 cells when treated with co-culture and control 
supernatants of various time points. (Healing after 24 hours).
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To study the effect of co-culture interactions on tumor cells wound healing of 
A549 was evaluated against appropriate controls (see section 2.3.8). The left hand panel 
of Figure 3.24 depicts the wound made by plastic tip of 200µl pipette tip while right hand 
panel depicts the healing after 24 hours after the wound.
The A549 cells treated with 4 hour A549-THP-1 co-culture supernatant shows 
significantly better healing than the rest (Figure 3.24). Cells treated with 24 hour co-
culture supernatant or 24 hour A549 only supernatant or untreated control showed 
marginal healing. We have already evaluated that the 4 hour co-culture supernatant is rich 
in TNF-α and IL-6 cytokines, implying that these cytokines might be involved in 
enhanced proliferation and invasiveness of the tumor cells. The 24 hour co-culture 
supernatant which contains cytokines like IL-10 does not seem to affect the migration 
properties of the tumor cells. Indeed, IL-6 activates STAT-3 pathway, a known 
mechanism to initiate cell proliferation.
3.7 TLR-2 dependant inflammatory responses may have implications for 
T-cell modulations
3.71 Culture supernatants from co-cultures of Tumor and adherent monocytes induce 
high Interferon-γ expression from Non-adherent monocytes (T-cell blasts)
The optimal functioning of NK and T cells is the critical feature of anti-tumor 
responses. The tumor cells are believed to suppress or regulate T-cell activation, averting 
tumor cell specific responses. The Non-adherent population from the buffy coat of Ficoll 
Paque treatment of blood cells mostly consists of T cell blasts or precursors (see section 
2.3.7). The Non-adherent monocytes (T cell blasts) were treated with Co-culture 
supernatant, Conditioned Medium treated macrophage culture supernatant and 
Conditioned Medium from tumor cells and after activating them with 10µg/ml anti-
CD3antibody and co-stimulating with 3µg/ml anti-CD28 antibody. The culture 
supernatants were collected at 48 hour and 78 hour time points and assayed for IL-2, IFN-
γ and IL-10. Curiously, no IL- 2 was detected in the culture supernatants (not shown 
here). Upon activation, IFN-γ was expressed in huge amounts by non-adherent 
monocytes. Non adherent monocytes (T cell blasts) treated with Co-culture supernatants 
showed enhanced expression of IFN-γ (Figure 3.25).
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Figure 3.25: IFN-γ expression in Culture Supernatants from Non-Adherent PBMCs 
co-cultured with Conditioned Medium, CM (30 hour) of (a) A549, (b) ChaGoK-1, (c) 
Caco-2, + adherent PBMC co-culture; 10µg/ml anti- CD3 and 3µg/ml anti-CD28
antibody coated. Data were represented as Mean Concentration of IFN-γ ± SD. Values 
were considered as statistically significant for p < 0.05 from atleast five independent 
experiments.
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Figure 3.26: IL-10 expression in Culture Supernatants from Non-Adherent PBMCs 
co-cultured with Conditioned Medium, CM  (30 hour) of (a) A549, (b) ChaGoK-1, 
(c) Caco-2, + adherent PBMC co-culture; 10µg/ml anti-CD3 and 3µg/ml anti-CD28
antibody coated. Data were represented as Mean Concentration of IL-10 ± SD. Values 
were considered as statistically significant for p < 0.05 from atleast five independent 
experiments.
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This was observed with all Tumor cell co-cultures and even with supernatants from 
tumor-conditioned media treated monocytes. Non-adherent monocytes treated with 
Conditioned medium from Tumor cells only, showed marginal inhibition of IFN-γ 
responses.
3.72 Interleukin-10 is readily expressed by Non-adherent monocytes (T-cell blasts) 
when treated with culture supernatants from Co-cultures
IL-10, responsible for mediating Th2 responses, was also assayed in the culture 
supernatants from anti-CD3-CD28 antibody stimulated Non adherent monocytes treated 
with Tumor cell-adherent monocyte co-culture supernatant, Conditioned Medium treated 
macrophage culture supernatant and Conditioned Medium from tumor cells. It is observed 
that medium from adherent monocytes, treated or untreated, elicits potent IL-10 induction 
from T-cell blasts, shown in figure 3.26.
Curiously, while assaying the anti-CD3-CD28 pre-activated and treated Non 
adherent monocytes, it is observed that Conditioned medium of ChaGoK-1 cells directly 
suppressed IL-10 expression from ex-vivo T-cells (Figure 3.25). This observation points
to differences between A549 and ChaGoK-1 cells, tumors of same origin, in triggering 
various cytokines and hence, varied immune responses from host immune cells.
Admitted, these observations need further validations.
Although not definitive, but this suggests the possibility of modulation of T-cells 
at early stages by tumor-macrophage based inflammation which could have implications 
for T-cell maturation as well as effector T-cell responses.
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A complex network of inflammatory mediators is involved in inflammation-
associated cancers. The links between inflammation and cancer have been confirmed in a 
number of experimental models, e.g., in liver and colon cancers. Macrophages are key 
cells in chronic inflammation and are recruited from monocvtes. Tumor-Infiltrating 
Macrophages (TIMs) are known to constitute a large part of tumors especially carcinomas 
(tumors of epithelial origin) and it is established that these TIMs are recruited from the 
circulating monocyte pool. The macrophages once in the tumor vicinity are ‘re-educated’ 
for a phenotype that is beneficial for tumor growth/progression/metastasis, which forms  a 
part of a broader concept of Immunoediting. In neoplasia, monocytes are recruited into 
the tumor from the peripheral circulation and are usually polarized toward an M2- like 
phenotype. However, there is little information on how macrophages attain this M2-like
phenotype. Initial understanding is that the tumor favoring phenotype is brought about by 
the crosstalk through the microenvironment of the tumor cells and is mainly determined 
by the cytokine/chemokine milieu i.e. combination of pro-inflammatory and anti-
inflammatory cytokines. The regulation of these cytokines skews the macrophage 
phenotype from Classical ‘M1’ to somewhat suppressed ‘M2’, also called TAM (Tumor-
Associated Macrophage) phenotype. Cytokines and chemokines influence movement of 
malignant cells and supporting stromal cells in primary tumors, and spread of cancer 
cells. This fine-tuned network influences the composition and phenotype of infiltrating 
immune cells and contributes to immunosuppressive polarized Th2 response. Some 
cytokines like TNF, IL-6, IL-10, IL-12, IL-1, IL-8, TGF-β are predominantly seen to be 
involved in generating such a milieu. Another important consequence of such cytokine 
milieu is suppression/regulation anti-tumor responses from Cytotoxic (NK & T) cells. 
This suppression is evaluated by studying the expression of cytokines specific to these 
cells like IL-2, IFN-γ, IL-10. 
In this study, we demonstrate that the interaction of carcinoma cells of different 
origins and monocytes, an important immune cell, is a two-way process and that cancer 
cells are also capable of modulating the monocyte phenotype in vitro. Following co-
culture there are dynamic changes in monocyte expression of mediators such as TNF-α, 
IL-6, IL-10, IL-12p40, generating a cytokine milieu in the typical of alternative 
activation. We have evaluated the cytokine expression when immune cells are present in 
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the immediate vicinity of the carcinoma cells especially lung carcinoma cells of human 
origin.
Tumor necrosis factor-α is produced by tumor cells or inflammatory cells 
promoting tumor survival. Indeed, TNF-α has been demonstrated to promote 
tumorigenesis as TNF-α-deficient mice or mice treated with anti-TNF-α antibodies are 
largely protected from the chemical induction of skin papillomas (Moore et al., 1999; 
Scott et al., 2003). TNF-α may also directly contribute to neoplastic transformation 
(Szlosarek et al., 2006). In humans, higher concentrations of TNF-α are found in the 
serum of cancer patients compared to control subjects, and correlate with decreased 
prognosis (Szlosarek and Balkwill, 2003). The fact that TNF-α is induced very early in 
the co-culture of tumor and monocytes emphasises the necessity of TNF-α in modulation 
of immune response against tumor cells. However, the amount of TNF-α required to bring 
out any tumor promoting modulations during tumor cell development would not remain 
the same and the same is underlined by strict regulation of TNF-α expression in all the 
experimental models shown in this work. The ability of TNF-α to further initiate further 
response might be dependent on achieving some kind of optimal or threshold levels as 
indicated by the kinetics of TNF-α triggered in all tumor types under study in this work.
The involvement of both IL-6 and STAT3 in malignant cell survival and 
proliferation has been well documented in numerous experimental systems (Aggarwal et 
al., 2006; Rose-John et al., 2006). Through the activation of genes involved in cell cycle 
progression and suppression of apoptosis, IL-6 can directly protect tumor cells from 
apoptosis. This work is indicative of acquiring such features for tumor cells as well as for 
monocytes. The unusually high concentration of IL-6 and its persistence in the co-culture 
supernatants could be enabling the properties of proliferation and apoptosis suppression. 
IL-6 has also been shown to act as an autocrine growth factor for tumors (Baffet et al., 
1991). Indeed, our assays confirm autocrine secretion of IL-6 but seem to be triggered by 
monocyte sensing, indicating intricate IL-6 based mutual crosstalk of the two cell types. It 
is known that IL-6 is essential in the initiation and maintenance of chronic inflammation 
of the colon (Atreya et al., 2000). Thus, profound secretion of IL-6 is definitely 
contributing to the inflammatory help required by various epithelial tumors. A high TNF-
α and IL-6 microenvironment points to the possible dependence of tumor initiation on 
inflammation while also serving as a prelude to more obvious anti-inflammatory 
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response. The pro-inflammatory cytokine like TNF-α, IL-6 rich cultures enhanced the cell 
migration and proliferative properties of the tumor cells. This is in accordance with the 
known tumor promoting abilities of IL-6 and TNF-α.
It is suggested that IL-10 possesses immunostimulatory activity that enhances 
antitumor immunity (Mocellin et al., 2004). Although IL-10 usually exerts antitumor 
activity, its biological effects are not all that simple, and consistent with its ability to 
activate STAT3, it might also promote tumor development. Direct effects of IL-10 on 
tumor cells that might favor tumor growth have been reported. For example, an IL-10 
autocrine and/or paracrine loop might have an important role in tumor cell proliferation
and survival. IL-10 has also been shown to modulate apoptosis and suppress angiogenesis 
during tumor regression (Sato et al., 2011). These dramatically opposing effects of IL-10 
might depend on interactions with either cytokines or factors found in the tumor 
microenvironment, as it is unlikely that IL-10 functions in isolation. In our experience, 
IL-10 is expressed by the monocytes when continuously cultured together with the tumor 
cells. It is safe to state that the late onset of IL-10 indicates that initial modulation by pro-
inflammatory cytokines is necessary for eventual take over by IL-10 to exert its effects. A 
better understanding of IL-10 signalling is needed before its effects on tumor growth and 
antitumor immunity can be fully explained. IL-12p40 is a subunit of IL-12 and IL-23 
cytokines but both are known to exert opposing inflammatory roles, where IL-12 is a pro-
inflammatory cytokine necessary for activation of anti-tumor NK cells and IL-23 is an 
anti-inflammatory cytokine involved in tissue rebuilding. The peculiar facet in the milieu 
of presence of IL-12p40 and absence of IL-12p70, the other IL-12 sub-unit strongly 
suggest IL-23 presence in the tumor-monocyte microenvironment. This is well in tune 
with the requirements of tumor as repair properties of IL-23 would aid in tumor 
progression. The absence of pro-inflammatory IL-1β from the cultures additionally 
strengthens the argument of active modulation of inflammatory responses that benefit 
tumor cells. The synchronised expression of IL-10 and IL-23, both known tumor 
promoting and anti-inflammatory cytokines, suggests this particular inflammatory milieu 
as an enabling characteristic for tumor cells of epithelial origin. Macrophages respond to 
microenvironmental signals and represent a spectrum of M1 to M2 phenotypes. The 
cytokine expression provides evidence of M2 like phenotype in monocytes. This M2-like 
phenotype, with an IL-10highIL-12low expression, of recruited monocytic precursors
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(Figure 4.1) is comparable to tumor associated macrophages. The tumor environment is 
thus, thought to educate tumor-associated monocytes toward a tumor-promoting 
phenotype but the mechanisms of this are not fully understood. 
It naturally follows that such novel expression of cytokines must be initiated by 
some trigger from the tumor cells which binds to a particular receptor on the monocytes. 
During tumor development, inflammation may be triggered by receptors recognizing non-
self molecules on tumor cells. The family of TLRs is an important mediator of the innate 
response, and activation of these receptors triggers the production of several molecules 
involved in anti-tumoral responses. Studies have indicated that TLRs have a crucial role 
in the development of tumours as they arise in their natural microenvironment, thus 
indicating an unknown aspect of tumorigenesis (Maeda et al, 2005; Naugler et al, 2007).
A formal role of TLRs in initiation with concatenate inflammation is yet to be 
determined. A strong possibility of the receptor for the monocyte based responses to be 
upstream of NF-κB, led to the evaluation of Toll like receptors as candidates. Of the 
known TLRs in mammalian system, TLR-2 and TLR-4 have known endogenous ligands.
Of course, the stimulus from tumor cells targeted TLR-2 on the monocytes as evident 
from blocking experiments. Nevertheless, the TLR-2 dependence for initiation of both 
types of cytokines underlines similarity of stimulus and mode of action. Interestingly, the 
engagement of TLR-2 is prevalent in all cell types and co-cultures under study, indicating 
universality of this phenomenon. Hence, the cytokine inducing tumor factor(s) is a TLR-2 
agonist, something not known in mammalian systems.
The regulation of the expression of TLR-2 agonist(s) would constitute another 
characteristic of tumor cells. This regulation expectantly could be based among the 
known oncogenic/tumorigenic pathways in the cancer cells. Screening for pathway 
inhibitors elucidated the involvement of MAP kinases, especially the MEK arm of the 
pathway in regulating expression of TLR-2 agonist(s). MAPK pathways are comprised of 
a three-tier kinase module in which a MAPK is activated upon phosphorylation by a 
mitogen-activated protein kinase kinase (MAPKK), which in turn is activated when 
phosphorylated by a MAPKKK. Mitogen-activated protein kinase (MAPK) pathways are 
evolutionarily conserved kinase modules that link extracellular signals to the machinery 
that controls fundamental cellular processes such as growth, proliferation, differentiation, 
migration and apoptosis.  As such, this pathway is strongly involved in various hallmarks 
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of tumorigenesis. MAP kinase pathways actually being involved in controlling of TLR-2
agonist(s) points to definitive role in tumor promoting inflammation. What is striking is 
the exclusion of Ras and Tyrosine kinase (EGFR) activity in regulating the TLR-2 agonist 
activity. This opens up the possibility of lesser known MAP kinase activating moieties 
that may lie upstream of MEK-1 activation. Noticeably, the p38 arm is also partially 
involved with TLR-2 agonist(s) control. This also potentiates MAP kinase checkpoints 
afresh for therapeutic targeting of tumors from the perspective of tumor related 
inflammation. The crux of the work presented here is schematically represented in Figure 
4.1. The data published in this study raises the possibility that recognition of tumor cells 
by macrophages, and vice versa, is important in initiating and, possibly, maintaining the 
cancer cytokine microenvironment, and may explain why there are abundant 
macrophages in the tumor microenvironment and modulated early while being recruited 
from monocytic pool.
In summary, the data presented here suggests that communication between tumor 
associating monocyte and tumor cells is based on cytokines represented in typical Cancer 
related Inflammation of the microenvironment. We demonstrate that cultured cancer cells 
of different origins promote monocyte differentiation toward a phenotype that resembles 
the alternatively activated state of Tumor Associated Macrophage (TAM). This switch 
involved a dynamic “chemical conversation” between the tumor cells and monocytes and 
is somewhat dependent on cell-cell contact. The novelty of this work is that we used a 
simple model system that shows that tumor cells actively modulate monocytes to generate 
tumor associated inflammatory phenotype of microenvironment via TLR-2 mediated 
cross-talk (Figure 4.1). The regulation of such synergy is not dependant on Ras or 
tyrosine kinase signalling but is instead MAP Kinase driven in tumor cells. This, in turn 
has consequences for proliferative properties of tumor cells, longevity of monocytes and 
perhaps, modulation of T-cell activity. This study provides a rationale for targeting 
monocytes and cytokines as a part of the tumor-promoting microenvironment in various 
carcinomas.
Even though this study provides fresh insights into tumor-monocyte interaction 
and the resulting inflammatory microenvironment, many unanswered and worthy 
questions have remained. A profound evaluation of the functional significance of each 
Figure 4.1: Schematic model representing TLR
MAP-kinase dependant factor(s) from human carcinoma cells triggering Can
related Inflammation.
-2 engagement on monocytes
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cytokine from tumor cells and immune cells is particularly interesting. Studies to 
understand the similarities and differences between the various tumor cell types presented 
in this study would help in deducing tumor progression mechanisms in each tumor 
subtype. Also, the strong possibility of other cytokines and chemokines also being 
triggered in co-cultures as shown in this work is worth persuading. The identification and 
characterisation of the TLR-2 agonist(s) could be objective of immediate study. The 
regulatory mechanisms involved in the expression of such TLR-2 agonist(s) could 
provide some therapeutic check points to tackle cancer.
It remains to be seen if anti-inflammatory molecules can deliver therapeutic 
benefit to patients suffering from large tumors, rather than serving merely a prophylactic 
role potentially preventing cancer occurrence.
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The conclusions from the present study can be summarized as follows:
• Human carcinoma cells trigger Cancer related Inflammation by expression of 
TNF-α, IL-6, IL-10, IL-12p40 but not IL-12p70 or IL-1β from monocytes. 
• TNF-α and IL-6 are induced early while IL-10 and IL-12p40 are expressed only 
after continuous interaction of the two cell types.
• Stimulus of tumor cell origin for these inflammatory responses is cell associated 
as well secretory (released) in nature.
• The factor(s) inducing these inflammatory responses during tumor and monocytes 
synergy is tightly regulated, as indicated by kinetics of cytokine expression.
• Cancer related Inflammatory responses are generated via engagement of TLR-2 
on monocytes.
• The expression of such typical cytokine milieu inducing TLR-2 agonist(s), from 
human carcinoma cells, is controlled by MAP-kinase pathway of intracellular 
signaling cascade.
• The TLR-2 agonistic activity of tumor cells is not dependent on activation of 
EGFR or Ras, the known oncogenic signals upstream of MAP kinases. 
• Early inflammatory response from monocytes promotes tumor cell proliferation.
• Tumor-monocyte interaction enhances monocyte viability. 
These results reveal a previously unrecognized pathway that might regulate activation 
of TLR2-dependent Cancer related Inflammatory responses during crosstalk of cancer 
and immune system.
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